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ABSTRACT
Resistance to conventional chemotherapy is a big challenge in the treatment of
cancer including non-small cell lung cancer (NSCLC). A combination of natural
chemo-sensitizer agents with chemotherapy offers unique advantages over monotherapy
alone. However, free unbound drugs, (in combination or as a single agent), lack tumortargeted accumulation and therefore can be easily eliminated from the patient body.
Moreover, some drugs are hydrophobic, and their organic solvents cause in vivo toxicity,
thereby limiting their capability in clinical translation. Herein, dual loaded biocompatible
and biodegradable nanoparticles (NPs) using Gemcitabine (Gem)a pyrimidine nucleoside
antimetabolite and Gambogic acid (GA) (a highly hydrophobic chemo-sensitizer agent)were developed on human serum albumin-tannic acid nano-platform (HTA) for targeted
treatment of NSCLC.
Our in vitro results demonstrate that Gem and GA combination therapy has
tremendous potential due to their high efficacy on NSCLC, and GA sensitize NSCLC to
Gem therapy. However, GA used in combination with Gem suffers from limited
solubility which subsequently leads to a decline in therapeutic efficacy. Therefore, in
order to overcome this, in the present study GA and Gem were encapsulated in human
serum albumin-tannic acid nanoparticles by the solvent evaporation method. In this
platform, HTA is a biocompatible nanocarrier that binds to both GA and Gem.
Physico-chemical characterizations studies revealed that GA and Gem are successfully
encapsulated in HTA NPs with uniform spherical morphology. These nanoparticles were
readily taken up by NSCLC cells (A549 and H1299) in a concentration and timedependent manner. Apart from an increase in GA solubility, encapsulated GA and Gem
subsequently manifested elevated therapeutic efficacy, which was confirmed by cell
viability, colony formation, migration and invasion studies. Furthermore, in vivo and ex
vivo imaging analysis demonstrated notable tumor-targeting behavior of our uniquely
designed HTA NPs in mice bearing A549 xenograft tumors.
These findings clearly illustrate that our dual loaded NPs can be efficiently
utilized to improve cancer therapy and tumor eradication.
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CHAPTER 1.

INTRODUCTION

Non-Small Cell Lung Cancer
Lung cancer, also known as bronchogenic carcinoma, is the leading cause
of cancer-related mortality among both men and women in the United States and
throughout the world1 2 3. In the United States alone, an estimated 228,150 new cases
have been diagnosed in 2019 and 142,670 patients have died from lung cancer4 5. In the
present year, it is predicted that lung cancer will lead to more deaths than breast,
prostate, and colon cancers combined together4. Based on the histopathological
appearance and morphology under the microscope, lung cancer is divided into two
categories: 1) Small cell lung cancer (SCLC) and 2) Non-small cell lung cancer
(NSCLC)6 7.
NSCLC represents about 85% to 90% of all lung cancer cases (~194 K new cases
in 2019). This category is further subcategorized as squamous cell carcinoma, large cell
carcinoma, adenocarcinoma and a mixture of undifferentiated carcinomas. NSCLC is
mainly asymptomatic in its initial stage; therefore, the majority of NSCLC patients are
often diagnosed at advanced stages, contributing to a five-year survival rate as low as
19%8. Unfortunately, by the time of diagnosis, 55% of NSCLC cases have developed
distant metastases throughout the patient’s body 9 10 11.
Available Treatment Options
Treatment options range from standard therapies currently implemented in
clinical practice to investigational treatments undergoing clinical trials. Table 1-1 lists
the stages of NSCLC and associated treatment strategies12 13. These options include:
x

x
x
x
x

Surgery: Consisting of pneumonectomy, lobectomy, segmentectomy or wedge
resection, and sleeve resection. Depending on the tumor size and the affected area of
the lungs, surgeons will remove either the entire lung or a segment of it. However,
one must bear in mind that resection of the lung, regardless of the quantity of tissue
removed, will lead to decline in lung function.
Radiofrequency ablation (RFA): RFA utilizes high-energy radio waves to heat and
burn the tumor. Usually patients who have low surgery tolerance and small tumors
located by the edge of the lung can take advantage of this procedure.
Radiation: Depending upon the stage of the cancer (localization and size)
radiotherapy might be considered as a primary treatment, pre/post surgery therapy.
Chemotherapy: The chemotherapeutic agents can be the only treatment option
remaining based on the stage of the cancer and overall health of the patient. We will
cover chemotherapy in more detail.
Targeted therapies: These treatment strategies could be designed to identify certain
molecular biomarkers on cancer cells and efficiently target and attack those cells. For
instance, epidermal growth factor receptor (EGFR) mutations are the most commonly

1

Table 1-1.

Different stages of NSCLC and tumor localization with associated treatment options.

Stage
Occult

Tumor localization
Tumor is hidden, cannot visualized by
imaging

Treatment
-

%Diagnosis
-

%Survival
-

0

Carcinoma in situ

Surgery

-

-

IA
&
IB

Only in lung without evidence of
regional lymph node or distance
metastasis

Surgery

15

75- 55

IIA
&
IIB

Spread to lymph nodes associated to
lung, no evidence of distance
metastasis

Surgery

-

50-40

IIIA
&
IIIB

Lymph nodes in tracheal area, or pop
lung and neck, no evidence of distance
metastasis

Surgery, chemotherapy,
radiation or combination

22

35-5

IV

Metastasis (regional and distance)
beyond chest

Chemotherapy

55

<5

Source: Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of
lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: 211–250

2

occurring mutations in NSCLC cells. Thus, targeted therapy with an EGFR inhibitor
(such as erlotinib, afatinib, gefitinib, etc.), could efficiently attack cancer cells by
attaching to EGFR receptors which are abundant on the surface of NSCLC cells.
Unfortunately, EGFR inhibitors may cause severe side effects such as acneiform rash,
which causes skin infections and hematologic toxicity, in addition to the rapid
development of resistance14.
Immunotherapy: The goal of immunotherapy is to establish and create personalized
therapy for NSCLC patients by exploring the immune checkpoints response.
However, this approach is associated with immune-mediated toxicity issues, e.g.
colitis, nephritis, pneumonitis and endocrinopathy15 16.

x

Targeted therapies and immunotherapy are among the most recent developments
in treating NSCLC. Over past few decades, substantial progress has been made, in all
possible respects, in improving the survival rate of lung cancer patients17 18.Currently, the
most desirable treatment strategy in clinical practice utilizes a combination of therapies19.
For initial stages of NSCLC, physicians generally suggest starting with local resection
and radiation therapy, followed by chemotherapy. However, as previously stated, the
majority of cases have reached advanced stages (III &IV) by the time of diagnosis,
precluding surgical intervention. Thus, the most elite treatment option remaining for
these stages is chemotherapy20
Chemotherapeutic Treatments for NSCLC and Their Drawbacks
To date, conventional chemotherapeutic anticancer agents, administrated either
orally or intravenously, is the most effective therapeutic regimen for NSCLC21.
Depending on the phase and stage of cancer, the chemotherapy can be administrated
pre-surgery (neoadjuvant), post-surgery (adjuvant) or as the predominant regimen
(advanced stages). The most common chemotherapeutic agents for NSCLC include:
x
x
x
x
x
x
x
x

Paclitaxel and albumin-bound paclitaxel (nab-paclitaxel, Abraxane)
Platinum-based agents (e.g. carboplatin and cisplatin).
Gemcitabine
Docetaxel
Irinotecan
Vinorelbine
Etoposide
Pemetrexed

Table 1-2 shows the result of a systematic research from ClinicalTrials.gov, a
publicly accessible website. This data was acquired by utilizing the advanced search
option and searching the term of “NSCLC” for the past decade (2009-2019), the search
was further narrowed by applying “completed” and “with result” filters. Of 184 trials
found in this analysis, we excluded those that did not reported “overall survival (OS)”
and “Progression free survival (PFS)”. Finally, the major chemotherapeutic agent

3

Table 1-2.

Clinical trials on NSCLC.

Chemotherapeutic
agent
Gemcitabine

Irinotecan
Paclitaxel

Nab- Paclitaxel
Carboplatin

Docetaxel

Combined anticancer agent
Zactima (ZD6474) + Vandetanib
Pemetrexed and Bevacizumab
Necitumumab
Custirsen sodium
Docetaxel
Cisplatin + axitinib
Cisplatin+ radiation
Oxaliplatin+ Etoposide+
Carboplatin
Pegylated irinotecan
Carboplatin
Cetuximab
pemetrexed
Imatinib mesylate
Ramucirumab
Olaratumab + carboplatin
Carboplatin
TRC105
Necitumumab +Paclitaxel+
Carboplatin
Bevacizumab-EU
nab-paclitaxel
ABP 215
OGX-427
Hydroxychloroquine
Bevacizumab+ Carboplatin+
Pemetrexed
Belotaxel
Ipilimumab+ Paclitaxel+
Carboplatin
Pemetrexed + Cixutumumab
Ramucirumab + Gemcitabine
Panitumumab+ Pemetumumab
Olaratumab + Paclitaxel
Gefitinib+Gemcitabine
+Carboplatin
Alectinib + Pemetrexed
Atezolizumab
Lurbinectedin
Gemcitabine + Lurbinectedin
mogamulizumab

4

OS
(months)
8.9
8.78
14.92
14.1
30
14.2
27.9
12.9

PFS
(months)
9.15
5.56
4.21
4.3
13.6
6.2
11.4
8.95

7.00
11.2
10.3
7.7
7.3
16.85
12.8
12.1
NA
13.2

2.66
5.8
6.4
3.8
3.6
7.85
4.77
6.3
3
5.4

16.02
14.52
6.6
10.8
NA
20.3

7.62
3.8
NA
6
4.2
12.6

10.6
10.7

3.6
5.5

NA
10.4
17.02
12.8
NA

8
5.6
5.75
4.77
9.7

27.8
15.7
5.5
7.2
8.88

10.9
2.8
16.7
6.1
1.87

Table 1-2.

(Continued).

Chemotherapeutic
agent

Vinorelbine
Etoposide
Pemetrexed

Combined anticancer agent
GSK3052230
Ramucirumab
Erlotinib
Eribulin Mesylate
Tivantinib + Erlotinib
Erlotinib [Tarceva]
LY2181308
Erlotinib+ Bevacizumab+
Erlotinib
Eribulin
Cisplatin
Zoledronic acid + Denosumab
GSK3052230+ Carboplatin
OGX-427+ Placebo
Erlotinib
Gefitinib
Eribulin
Tivantinib+ Erlotinib
Bevacizumab, Carboplatin,
Cisplatin + Cixutumumab
Cisplatin+ Folic acid
Cisplatin+ LY2603618
Ramucirumab + Carboplatin
+Gemcitabine

OS
(months)
NA
15.15
7.1
9.5
6.8
5.61
7.9
11.86
9.5
10.3
10.9
4.1
10.8
5.8
10.8
9.5
6.8
20.3
10.68
34.6
12.9
10.4

PFS
(months)
4.6
5.22
1.6
3
7.3
2.33
2.8
4.01
3
NA
5.7
NA
6
1.8
4.0
3.0
7.3
12.6
5.45
12.4
4.7
5.6

Source: U.S. National Library of Medicine. https://clinicaltrials.gov/ct2 accessed
October 19, 2019.
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that the studies utilized259. Table 1-2 demonstrates that the major trial studies conducted
in the past ten years are combination studies of chemotherapeutic agents with another
anticancer agent in order to increase patient OS and PFS.
As shown in Table 1-2, most of the chemotherapeutic agents have achieved only
modest survival improvements due to limitations such as chemo-resistance, relapse,
cancer recurrence, intolerable toxicities (as a result of excessive drug usage), and severe
side effects. Chemotherapeutic side effects are often due to unspecific targeting, in which
the drug attacks healthy cells as well as cancer cells. Since cancer cells are derived from
normal cells, conventional agents are unable to differentiate between them. For instance,
they can attack neurons and damage nerves, causing peripheral neuropathy. However,
gemcitabine (Gem) has shown a safer toxicity profile than other available chemotherapy
agents for NSCLC therapy, with improved PFS and OS with Gem/platinum treatment
rather than taxol/platinum treatments22 23. The clinical benefit of Gem, which has the
highest average OS rate (~17 months) among chemotherapy options, while carboplatin
and docetaxel have ~12 months and ~10 months average OS respectively, are placed in
the second and third best positions.
Moreover, a review on 37 randomized phase III clinical trials with more than
15,000 participants, conducted by Langer et al. to investigate the effect of Gem as first
line therapy for NSCLC patients, revealed that Gem as a monotherapy showed similar
effects to platinum-based monotherapy for advanced and/or metastatic NSCLC, but with
the advantage of having less toxicity. According to this analysis, Gem combination shows
a statistically significant benefit-risk ratio with regard to OS and PFS in comparison to
platinum-based drug combinations24. However, there is a risk of rapid development of
resistance to Gem and also of systemic toxicities when combined with other
chemotherapeutic agents, we will cover this subject in more detail.
There is an emerging need for optimization and validation of new therapeutic
strategies to make the most of Gem therapy for NSCLC and to circumvent its associated
difficulties.
Gemcitabine and Its Mechanism of Action
Gemcitabine (Gem) [2'-deoxy-2',2'-d ifluorocytidine monohydrochloride
misomer); dFdC] is a potent chemotherapeutic anticancer agent (Figure 1-1a). Approved
as a cancer therapy by the Food and Drug Administration (FDA) in 1998, Gem has been
used as a first and second-line treatment of NSCLC, both as a single agent and in
combination regimens25 26. Due to its unique mechanism of action, Gem is the most
commonly used chemotherapeutic agent for treating advanced NSCLC 27.
Gem, a prodrug, is a nucleotide (deoxycytidine) analog falling under the category
of antimetabolite anticancer agents. Upon internalization to cancer cells, the drug
converts to its active form via a phosphorylation process catalyzed by deoxycytidine
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Figure 1-1. Chemical structure of (a) gemcitabine and (b) gambogic acid.
(a) Chemical name of Gem is (2'-deoxy-2',2'-d ifluorocytidine monohydrochloride
misomer); dFdC, with chemical formula of C9H11F2N3O4.
(b) Chemical name of GA is (Z)-4-[12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]2-methylbut-2-enoic acid, with chemical formula of C38H44O8.
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kinase. The kinase converts it to the diphosphate and triphosphate forms. The
triphosphate metabolites compete with deoxycytidine triphosphate and promote
termination of the DNA chain synthesis. Therefore, Gem acts as an inhibitor of DNA
replication, leading to DNA fragmentation, and ultimately causing cell death and
apoptosis. Once Gem has been activated inside the cells, self-potentiating activities of its
di- and triphosphate forms initiate. This process enhances its anticancer effect by
increasing its intracellular concentration above the level of deoxycytidine triphosphate,
its competitor in DNA synthesis.
Gem advantages as compared to other nucleoside analogues in NSCLC therapy
include 1) active transport through the cell membrane, 2) efficient phosphorylation, 3)
ability to self-potentiate, 4) slower elimination rate, 5) good pharmacokinetics profile, 6)
increased cell permeability and 7) lower toxicity28 29. Moreover, extensive amount of data
from phase II studies supports that Gem (Gemzar) has response rate of 21% on NSCLC
as a single drug and also it was able to escalate the median survival rate of NSCLC
patients by 20-25%, or approximately 9 months27 . Taken together, this evidence would
suggest that Gem is an ideal chemotherapeutic candidate for NSCLC therapy.

Challenges of Gemcitabine Monotherapy
Despite the promising results associated with Gem therapy for NSCLC, the drug
may not achieve optimal therapeutic efficacy due to the development of resistance by
cancer cells. Initially, patients may respond favorably to Gem-based chemotherapy but
will eventually experience a significant decline in response 30 31. In general, cancer cells
develop resistance by a number of mechanisms, including 1) reduction of drug uptake or
increase in drug efflux by cells, 2) increased tolerance and fast repair of damaged DNA in
cancer cells, or 3) altered drug activation factors by intracellular elements32 33. Evidence
suggests that mechanisms of resistance cause a drastic decrease in cellular uptake of
Gem34. Cells may develop resistance to Gem either by intrinsic or acquired pathways
involving molecular and cellular variations, such as changes in nucleotide metabolism
enzymes, apoptosis pathways, and induction of ATP-binding cassette transporter
expression 35. Furthermore, it has been reported that Gem-related chemoresistance is
associated with reduced cellular uptake due to defective human concentrative nucleoside
transporter 1 (hCNT1) and human equilibrative nucleoside transporter 1 (hENT1), which
are required for Gem influx, as well as overexpression of ribonucleotide reductase
activity and decrease in deoxycytidine kinase (DCK) expression 36 37. Another important
factor for the development of chemoresistance is the deamination of Gem by cytidine
deaminase (CDA), which plays a critical role in Gem metabolism. Deamination converts
Gem to its inactive form, and studies support that the over-expression of CDA is
associated with Gem resistance 38. Moreover, significant number of studies indicate that
the over-expression of the ribonucleotide reductase (RR) enzyme, which is directly
associated with Gem’s self-potentiating process and is responsible for conversion of
nucleotide diphosphates (NDPs) to deoxyribonucleoside triphosphates (dNDPs) during
DNA synthesis, has great impact on cell resistance to Gem therapy 39 40 41 42 43.
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Gemzar® is the chemically modified version of Gem (a hydrochloride salt form)
produced by Eli Lilly and Company in the expectation of increased potency, but, along
with a slight increase in side effects, it is also more susceptible to deamination,
decreasing its half-life to 15 minutes 44.
To date, anticancer agents have been used both as single agents and in
combination regimens. Combination therapies are continuously being explored and have
already gained significant attention. The synergistic effect of combining therapeutic
agents improves patient response and reduces the development of drug resistance by
cancer cells. Particularly for lung cancer therapy, an increasing body of evidence suggests
that the utilization of a single anticancer drug confers a high failure rate as a
consequence of the complex nature of this cancer19 45. Thus, devising effective
combination regimens that overcome the multivdrug resistance (MDR) phenomenon
remains desirable in the clinical setting.
As Gem exhibits mild toxicity, it is a superior candidate for combination therapy
regimens. The copious literature available on PubMed on Gem combinations with other
anticancer agents for NSCLC therapy supports the importance of the co-administration of
Gem in order to elevate its level of efficacy (Figure 1-2). Combination therapy not only
will help to maximize the therapeutic efficacy of Gem, but also minimize the
development of intrinsic and acquired resistance toward Gem therapy, while reducing
overlapping side effects for enhanced tolerability28. These are all feasible as usually
combined drugs have distinct molecular mechanisms of action.
Current Gemcitabine-Combination Therapies and Their Drawbacks
Currently, there are multiple preclinical and clinical trials designed to enhance
Gem therapy outcome by combining it with other therapeutic agents. As shown in Figure
1-2 most of the combination therapy studies with Gem have been conducted with
cisplatin; five phase II investigations have been carried out with different dosages and
scheduling, with a median response rate of 38-54% and elevated median OS rate to
8.4-14.3 months 46. In another randomized phase III clinical trial, Cardenal et al (1997)
studied in 136 NSCLC patients, to compare and investigate the combination of cisplatin
with Gem and etoposide. Unsurprisingly, the Gem group had a response rate as high as
46% with lower toxicities, while the etoposide group had a 22% response rate47.
Furthermore a combination of cisplatin and Gem e led to a 46% reduction in drug
resistance48. However, this type of combination regimen is associated with clinically
relevant adverse effects such as neutropenia, neuropathy, thrombocytopenia,
myelosuppression, and nephrotoxicity. These side effects were around 3 or 4 with respect
to the World Health Organization grading system. Grade 3 accounts for severe adverse
effects and grade 4 for life threatening or disabling adverse effects49. Therefore, future
directions on NSCLC therapy are more focused on less toxic, particularly non-platinum
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Figure 1-2. Graphical representation of number of peer-reviewed articles, book
chapters and reviews, published on Gem combination with different anticancer
drugs to treat NSCLC cancer.
This data was compiled from PubMed (1994 -2019).
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combinations, as their risks are higher than their benefits especially for unfit patients with
compromised health issues. Hence, we speculate that the combination of Gem with a
chemo-sensitizer/anticancer agent with a more favorable safety profile, would open up a
new horizon for the future of NSCLC therapy. A combination such as this may achieve
greater treatment efficacy, delay or eliminate development of drug resistance, and reduce
toxicity.
Use of Natural Compounds in Cancer Therapy
Since ancient times, natural compounds have shown a broad range of therapeutic
potential for the treatment of various diseases. Currently, there are a multitude of these
natural products available on the market. Therapeutic applications relate to antiviral,
anti-inflammatory, chemo-preventive and chemo-sensitization properties, etc.50 Most
common categories of natural compounds that have shown to have anticancer properties
include polyphenols, phytochemicals, and xanthonoid.
According to a statistical electronic search on PubMed, there are around ten
thousand studies conducted on effects of natural compounds on cancer since 1981.
However, the majority of these compounds have exhibited a decline in interest during
drug discovery due to lack of potency. For example, tannic acid and curcumin have
shown very promising inhibitory results on multiple oncogenic signaling cascades and in
different cancer types. Unfortunately, their use in this context is unfeasible due to the
high concentration required to achieve sufficient potency Interestingly, gambogic acid is
among a few natural compounds that demonstrates somewhat potent anticancer properties
within an acceptable dosage range50. For better Table 1-3 , shows the half-maximal
inhibitory concentration (IC50) in A549 and H1299 (NSCLC cell lines) of resveratrol,
tannic acid, flavonoids, curcumin, epigallocatechin gallate (EGCG) and mangiferin.
Among above mentioned studies approximately seven thousand of them are
related to combinations of natural compounds with either chemotherapeutic drugs or
other anticancer compounds. Not surprisingly, around 3,500 of these combination studies
were conducted in last five years, indicating the emerging interest in using natural
compounds as a co-treatment agent to act synergistically or additively toward better
anticancer efficacy. Figure 1-3 presents a graphical representation of the number of
publications conducted on combinations of known natural compounds with commonly
used chemotherapeutic agent in NSCLC. We have focused on combination studies
conducted using the natural compounds mentioned above with our drug of interest, Gem,
on NSCLC therapy published in the past five years, and a total of three studies have
emerged. In one, Mirza et al. (2017) investigated the effect of curcumin in combination
with Gem on NSCLC, and their results curcumin remarkably decreases the self-renewal
ability of stem cells and, when combined with Gem, was able to decrease the IC50 of
NSCLC cell lines compared to Gem alone. They suggested that this is due to induced
DNA damage and/or inhibition of repair mechanisms by curcumin 51. Another study by
Zhang et al. (2018) developed a liposomal curcumin dry powder inhaler, and they
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Table 1-3.
Range of IC50 for different natural compounds on NSCLC cell lines
(A549 and H1299).
Natural compound

Ref.

Resveratrol

IC 50 on NSCLC(μM)
A549
H1299
<90
45-51

Tannic acid
Vitamin D

20-30
50-60

15-27
35-45

-

Curcumin
EGCG
Gambogic acid

48-53
<300
1.2-1.55

20-30
170-210
0.9-1.2

54,55

52

53

56
57

Figure 1-3. Graphical representation of number of publications compiled on
frequently used natural compounds in NSCLC therapy.
Flavonoids, resveratrol, epigallocatechin gallate, Mangiferin, tannic acid, curcumin,
gambogic acid with chemotherapeutic agents that are commonly employed in NSCLC.
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sprayed the powder, curcumin, and Gem on the lungs of rats with lung cancer. Their
results indicated that liposomal curcumin dry powders had higher antitumor efficacy,
modulating the expression of VEGF, malondialdehyde, TNF-α, caspase-3, and BCL-258.
However, both studies mentioned low water solubility, weak bioavailability and rapid
metabolism as the main limitations of curcumin. Moreover, Lee et al. (2015) investigated
the chemo-sensitization ability of quercetin, a bioflavonoid, on lung cancer. They
demonstrated that not only does quercetin decreases cell growth in lung cancer, but it also
sensitizes them to Gem therapy through inhibiting HSP70 expression. At the same time,
quercetin increased side effects such as headache, nausea and vomiting, kidney damage,
numbness and tingling of fingers, and shortness of breath59. Interestingly, gambogic acid
is among a few natural compounds that demonstrates somewhat potent anticancer
properties within an acceptable dosage range, with safer toxicity profile 60, therefore,
setting forth a suitable component for successful combination therapy.

Natural Chemo-Sensitizer Agent: Solution for Gemcitabine-Combination Therapy
Gambogic acid (GA, chemical formula: C38H44O8) is a small molecule isolated
from the brownish/orange gamboge resin of the Garcinia hanburyi tree (Figure 1-1b) 61.
Due to easy isolation, GA supply is abundant. Previous studies reported that GA has
antineoplastic effects and is a potent apoptosis inducer62. It also has a favorable safety
profile and large therapeutic index63 64. On one study, due to emerging interest to use GA
as an anticancer agent general pharmacological aspects, toxicity and analgesic properties
of GA investigated on dogs and mice to check the effect of GA on cardiovascular,
respiratory and central nervous system (CNS), which suggested minimal effect on blood
pressure, heart rate and respiratory system. Beside administrating really high dosage of
GA(>16mg/kg) exhibited minor and insignificant side effects on CNS in mice. In
addition GA showed high analgesic activity which could be connected to its
anti-inflammatory nature65.
Furthermore, GA is amenable to chemical modification, has been approved for
phase II clinical trials in solid tumor therapy, and is approved by china food and drug
administration (CFDA) as an anticancer agent for lung cancer therapy specially
NSCLC66 67 68.
Accumulated preclinical and clinical evidence indicates that GA has a significant
anticancer effect on various types of cancers including NSCLC, breast cancer, and
prostate cancer, by targeting different molecular pathways (Table 1-4). This evidence
demonstrates the broad range of mechanisms of action and excellent potency of GA. Its
anti-tumor effects include, but are not limited to, induction of apoptosis, accumulation of
reactive oxygen species, autophagy, cell anti-proliferation, and inhibition of enzymes
(e.g. telomerase) and growth factors (e.g. VEGF), and interception of NF-κB signaling
pathways. In addition to all of that, Duan et al. (2013) have reported that healthy cells
exhibit less sensitivity to GA compared to cancer cell lines, presumably due to redox
homeostasis69.

13

Table 1-4.

Molecular targets of gambogic acid.

Molecular target
category
Kinases

Effects on biomarkers
↓Akt, ↓ JNK1, ↓CDk7, ↓ p34, ↓ p38-MAPK, ↓PI3K, ↓ SRC3,
↓pMET, ↓pERK1/2, ↓ ERK, ↓ Focal Adhesion Kinase,
↑p21waf/cip1, ↓CDC2, ↓Tyrosine Kinase

Growth factor
signaling

↓VEGF, ↓EGF, ↑ p21, ↑p27, ↓PDGF

Receptors

↓VEGFR, ↓VEGFR2, ↓ EGFR, ↓PDGFR, ↓KDR/FLK1

Apoptotic proteins

↓Bcl2, ↑ Bax, ↑ Caspase3,8 &9, ↓c-FLIP, ↓Survivin, ↓Bad,
↓Bid

Transcription factors

↓HlF-1α, ↓ NF-ƙb, ↓ hTERT, ↓MYC, ↑FOXO3, ↓STAT3

Enzymes

↓Telomerase, ↓ MMP-2, -9, ↓Thioredoxin reductase, ↓
PHD-2, ↓PARP

Oncoproteins and
tumor suppressor
gene

↓cMYC, ↓ MDM2, ↓ P MET, ↓P53

Others

↑ LRIG1, ↑ROS, ↑SIRT1, ↑ DOX, ↑DRS, ↑ BCR-AB1, ↑
RECK, ↓CYCLIN D1, ↓CD31, ↓CALUMENIN, ↓HSP90,
↓PXR, ↓IL-5

Source: Banik, K. et al. Therapeutic potential of gambogic acid, a caged xanthone, to
target cancer. Cancer Lett. 416, 75–86 (2018).
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Most importantly, GA has shown chemo-sensitization properties in different types
of cancers70 63 . In general, chemo-sensitizers are small molecules that make cancer cells
more sensitive to chemotherapeutic agents, thus improving the therapeutic index and
antitumor effects of these agents. These compounds are also known as resistance
modulators, which inhibit or block drug efflux from cancer cells via the P-glycoprotein
(P-gp) pump and elevate the concentrations of therapeutic agents inside MDR cells71.
Previously, GA has been combined with other chemotherapy drugs, to enhance
the antitumor efficacy synergistically or additively, such as its combination with
5-fluorouracil (5-FU) on gastric cancer treatment, exhibiting significant effect of tumor
regression. Also, cotreatment with low dose of GA, elevated the efficacy of docetaxel on
docetaxel-resistant gastric cancer cell lines via down regulation of survivin72. These
findings support the concept of using GA as a chemo-sensitizier agent for conventional
chemotherapy. GA not only serves as a P-glycoprotein inhibitor to reduce MDR via the
post-translational proteasome signaling pathway, but also down-regulates the expression
of ribonucleotide reductase enzyme subunit-M2 (RRM2) via (ERK)/E2F1 signaling
pathway. As discussed previously these are two main causes of development of resistance
toward Gem 73 74 75.
Altogether, combination therapies such as this may combat drug resistance.
However, side effects in healthy cells resulting from off target toxicity remain a
challenge. Further, GA is a hydrophilic molecule, which leads to limited passive
diffusion, and its organic solvents cause severe systemic toxicity in vivo. Moreover,
based on its relatively low molecular weight, GA is eliminated quickly from the body
after administration, leading to a short half-life in the blood. These limitations are also
obstacles to the use of GA monotherapy. Hence, there is an urgent need to improve
current treatment strategies and to develop appropriate drug delivery systems that will
produce more robust therapeutic effects and promote successful utilization of natural
compounds in chemotherapeutic co-therapies in clinical practice.
Nanomedicine
Nanomedicine and nano-drug delivery systems (NDDS) have been employed to
conquer the disadvantages of conventional drugs. The value of nano drugs expected to be
developed by 2025 has been estimated at $350.8 billion according to a report released by
grand view research, Inc. To date, over 75 nanomedicine formulations have been
approved by the FDA, and they are currently being utilized in clinical practice76.
Nanoparticle formulations for cancer therapies have gained significant attention,
as chemotherapeutic drugs loaded on nanocarriers have shown several advantages over
conventional formulations. Nanoparticle (NP) delivery systems reduce the side effects of
conventional chemotherapy via more efficient drug delivery to the tumor site. They also
lower the dosage needed for administration and reduce the possibility of acquiring drug
resistance toward chemotherapeutic agents.
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The rationale behind using NPs is based on their delivery approach, which
increases accumulation at the tumor site via the enhanced permeation and retention (EPR)
effect77 78 79. NPs prolong circulation time and improve tolerability concerns by
decreasing toxicity issues. These advantages relate to their appropriately designed size
(~100-400nm), which allows them to easily bypass the reticuloendothelial system (RES)
yet take advantage of the EPR effect due to leaky tumor vasculature. These deformed
blood and lymphatic vasculatures arise from irregularities in their membranes upon rapid
angiogenesis during the development of tumor tissues 80 81.
Consequently, the pharmacokinetic, pharmacodynamic and bioavailability
profiles of therapeutic agents encapsulated in NPs is favorably enhanced by expanding
their half-life and blood circulation time. NPs allow the drug enough time to be in close
contact with the tumor microenvironment to efficiently penetrate and accumulate in
tumor tissues and release the drug cargo at the tumor site. 82 83 84. The other
physicochemical properties of NPs, such as surface charge, are an important factor for
utilization of any designed NPs for a drug delivery system. During development, it is
highly desirable to achieve a negative zeta potential that decreases the risk of systemic
toxicity and formation of NP aggregates, while also increasing the internalization of NPs
within cancer cells. Moreover, nanoparticles can increase the water solubility of
hydrophobic drugs. Although Gem is a water-soluble agent, GA suffers from water
insolubility, and organic solvents of hydrophobic drugs cause in vivo toxicity, thereby
limiting their clinical use85. Furthermore, NPs can reverse MDR, as they can promote the
efficient uptake of drugs by cancer cells 86 87 88, Also, combination regimens with
chemotherapeutic agents often suffer from poor bioavailability and off-target toxicity,
drastically decreasing their efficacy, whereas nanotechnology strategies promotes
targeted and efficient delivery of anticancer cargo.
In general, nanomedicine for cancer therapy consists of a carrier vehicle and a
drug. Some NPs may be conjugated with a targeting moiety as well. There are various
types of carrier designs, which can be utilized in NCLC therapy that are listed below their
schematic representation are shown in Figure 1-4.
Lipid-based nanocarriers: This group of nanoparticles are composed from
phospholipids; they are consisting from two major groups; liposomes and micelle. Lipid
based nanoparticles can encapsulate both hydrophobic and hydrophilic drug due to their
lipid layer and aqueous core, respectively. They can increase the blood circulation time
and reduce the RES clearance. By conjugating with polyethylene glycol (PEG), this
liposome can reach to higher tumor accumulation, enhanced the permeability and
retention effect, and excellent biocompatibility89.
Polymer-based nanocarriers: This category of NPs is synthesized from
polymers, major groups in this category consists of polymeric micelles, polymersomes,
polyplexes, polymer-lipid hybrid systems, and protein systems. Polymeric nanoparticles
can be developed by self-assembly formation between two or more polymers.
Accumulated data indicates that they are able to co-delivery hydrophobic and hydrophilic
drugs and improve the anticancer effect, due to increased tumor penetration of drugs 90.
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Figure 1-4. Schematic representation of different types of nanoparticles that have
been used in NSCLC therapy.
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Protein-based self-assemblies are also being investigated for NSCLC therapies as
they are biodegradable, biocompatible, and can be conjugated to drugs and release them
easily in the tumor environment. A successful example in this group is Abraxane, an
FDA-approved albumin-bonded paclitaxel for NSCLC and also other cancers such as
breast and ovarian cancer91 92.
Metal-based nanocarriers: Another category of the nanocarriers are metal NPs
designed mostly with silver and gold, recently they have been widely used in biomedical
application more focused on diagnostic studies, for instance, discrimination of the
histological aspects of lung cancer and healthy cells. Magnetic nanoparticles, fails under
this category and generally shown the encouraging properties for cancer therapy93.
Other nanocarriers: Other NPs, such as mesoporous silica, commonly used in
drug delivery studies due to their loading capacity and drug release properties. Their main
mechanism for internalization to NSCLC is via endocytosis. Due to their multifunctional
properties, these NPs can also be used in intercellular labeling and magnetic resonance
imaging investigations.
Dendrimers nanoparticles is a class of nanocarriers with broad functional
properties, ranging from drug delivery to nanodevice. For drug delivery applications, they
can either entrap the drug via noncovalent interactions (formulation approach), or
covalently couple with drugs (nano-construct approach). Dendrimers consist of multiple
branches, providing enough surfaces for drug conjugations. They have been used
frequently for platinum-drug delivery, and have been able to increase solubility and
loading payload and also decrease the toxicity and selective penetration of the drug in
tumor tissue, leading to improvement in anticancer efficacy94 95 96.
Table 1-5 gives detailed information on nanocarriers designed especially for
targeting NSCLC and their outcome.
Passive Targeting and Active Targeting
Nanoparticles usually target cells through two main mechanisms: 1) Passive
targeting; whereby nanoparticles are able to take advantage of the EPR effect and
passively diffuse to the tumor site and accumulate in tumor tissue due to enhanced
circulation time, and 2) active targeting; whereby attaching specific affinity ligands to
the nanoparticle surface facilitates its recognition by receptors on the cancer cell surface
and assists its uptake by tumor cells via a receptor-mediated endocytosis mechanism. It is
noteworthy to mention that there is usually a possibility to modify the surface of
nanoparticles with ligands to promote active targeting in order to more precisely
recognize the tumor cells and increase their uptakes by tumor cells.
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Table 1-5.
Examples of various types of nanocarriers studies in preclinical and
clinical trials leading to improved antitumor efficiency of different
chemotherapeutic drugs on NSCLC.
Nano-carrier type
Lipid-based nanoparticle
(Lipoplatin)

Drug conjugated
Cisplatin

Lipid-based nanoparticle
(Lipusu)

Paclitaxel

Lipid-based nanoparticle
(Liposomal Paclitaxel)

Paclitaxel

Lipid-based nanoparticle
(Self-assembled platinum)

Cisplatin
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Study results
Phase II and III
clinical trial,
similar OS to
Cisplatin (59.22%
vs. 42.2%) plus
significantly lower
toxicity.
Higher efficacy in
comparison to
plain Paclitaxel,
also clinical
studies conducted
on its
premedication on
solid tumors,
including 60
NSCLC patient,
supporting the
elevated level of
antitumor potency.
A phase I clinical
trial and PK study
showed lower
toxicity and better
PK profile, with
OS rate of 54.5%.
Harnessing
structure-activity
relationship (SAR)
for localized drug
release, improved
cisplatin efficacy
on inhibiting the
tumor growth, and
remarkably
reducing the
toxicity.

Ref.
,

97
98

99 100

,

101

102

Table 1-5.

(Continued).

Nano-carrier type
Polymeric Micelles
(NK012)

Drug conjugated
Irinotecan

Polymeric Micelles
(Genexol-PM)

Carboplatin+
Paclitaxel

Polymeric Micelles
(Pluronic P123/F127
mixed micelles)

Paclitaxel

Metal-based nanocarrier
(Gold nanoparticle
(AuNP))

Polyacrylic acid (PAA)coated cerium oxide
nanoparticles (PNC)

Doxorubicin (Doxo)
and Hsp90 inhibitor
ganetespib (GT)
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Study results
Increased
accumulation of
Irinotecan in tumor
cells, and
enhancement of
antitumor activity
was observed.
Phase II clinical
trial exhibited
significant efficacy
improvement as a
first line treatment,
OS rate= 35.7%
Currently is in
market in Korea.
In vitro and in vivo
studies showed
elevated level of
antitumor efficacy,
decreasedIC50,
and tumor volume
on a A549
xenograft tumor.
Improved tumor
necrosis factor
related apoptosis
inducing ligand
(TRAIL)
sensitivity via
dynamin-related
protein 1 (Drp1)
apoptosis.
Synergistic
antitumor effect of
Doxo and GT was
observed, via
increase ROS, and
80% cell death on
in vitro assays.

Ref.
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104 105

,

106

107

108

Table 1-5.

(Continued).

Nano-carrier type
Lipid-based nanoparticle
(Lipid/Calcium/Phosphate
nanoparticle (LCP)

Drug conjugated
Gemcitabine

Gelatin nanocarriers
(GNCs) cross-linked with
Genipin (Gem-GNCs)

Gemcitabine

Polymeric- based
Nanocarriers
(Albumin-bound
paclitaxel)

Paclitaxel

(lipid Nanocapsule-based
gel)

Gemcitabine

Dendrimer
(4 PAMAM-dendrimer)

N2, N4dibenzylquinazoline2,4-diamine (DBeQ)
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Study results
Co-delivery of
siRNA targeting
VEGFs and
gemcitabine, in
vitro and in vivo
studies supports
escalated level of
tumor cell
apoptosis.
Developed through
Taguchi design,
decreased IC50 of
NSCLC cell lines
by 5-fold.
FDA approved for
NSCLC therapy
Good safety
profile. Elevated
antitumor efficacy,
Lipid based
nanogel targeted
the lymph nodes,
less toxicity and
better
biodistribution.
DBeQ was
successfully
encapsulated in
dendrimer and
significantly
decreased in cell
proliferation,
migration and
tumor growth.

Ref.
109

110

111

112

95

Nontechnology-Based Gemcitabine Therapeutics
Literature evidence support that NP-mediated delivery of Gem is able to reverse
the associated resistance in various cancer types mainly through following aspects: 1)
increasing Gem uptake by cells via EPR effect and overcoming the deficiency of
nucleoside transporters 113, 2) reducing the ribonucleotide reductase(RR) enzyme
expression114 115, 3) reducing the deamination process by conjugation to either a fatty acid
or another chemotherapeutic agent (e.g. paclitaxel) to protect the Gem from CDA enzyme
and inhibit deamination91 116 117 118 .
Accordingly, nanomedicine has had some positive impact in increasing the
efficacy of Gem on NSCLC, supported by rising numbers of preclinical and clinical
studies in this regard. Wonganan et al. (2012), studied the co-delivery of RRM1-specific
small interfering RNA (siRNA), conjugated with polyethyleneimine, which was able to
significantly enhance the tumor regression in the mice bearing RRM1-overexpressing
tumors. Likewise, Khatri et al. (2015) investigated the sensitization effect of cyclic
arginine-glycine-aspartic conjugated siRNA nano-constructs on Gem in NSCLC, and
their results indicates that with successful delivery of siRNA facilitated by
nanoformulation, they were able to lower the IC50 of A549 cells compare to Gem alone,
and reduce the expression of the RR subunit119.
Furthermore, two phase II clinical research was conducted on Gem delivery to
NSCLC by Genexol-PM nanoformulation. Genexol-PM is a cremophor-free
nano-formulation of paclitaxel developed with PEG and polylactic acid for treatment of
lung cancer. In one study, 43 patients were subjected to 230 mg/m2 and Gem 1,000
mg/m2 for a three-week period, as a first line treatment. The results showed overall
survival rate was 46.5%, and average OS and PFS were 14.8 and 4.0 months respectively,
with side effects of anemia, asthenia, myalgia and peripheral pneumonia120. A similar
phase II trial was performed utilizing Genexol-PM in combination with cisplatin, in
which the median dose of Genexol-PM was higher, but the OS rate was lower (37.7%). In
addition, given the concerns about the side effects associated with the platinum-based
therapy, co-delivery of Gem with Genexol-PM was more satisfactory in NSCLC
patients105.
Self-Assembly Nanocarriers
Artificial nanoparticles have been utilized in drug delivery for many years and
were able to serve their purpose, more or less. There are numerous nano delivery systems
developed every year in laboratories, however, when exposed to more complicated in
vivo modeling for preclinical and clinical trials, they often encounter some limitations
leading clinical failure. These limitations involve stability in systemic circulation,
immune responses, and issues with compatibility and degradation. Therefore, there is an
emerging necessity to use more stable, biocompatible and biodegradable materials for
drug delivery systems, with fewer immunogenicity and toxicity issues, in order to achieve
a superior approach for encapsulation of therapeutic drugs.
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Hence, protein-based self-assemblies (SAs) are being utilized for nanocarrier
development. Proteins are non-toxic and can easily degrade into their subunits (amino
acids), which can eventually be reused by peripheral tissue121. These self-assembly-based
nanoparticles are easily fabricated and tailored designed methods can provide stable
platforms. In addition, we should not forget that SAs can extend a drug’s half-life and
blood circulation time, as well as readily benefit from passive targeting. They can also be
modified for active targeting. SAs often form covalent conjugations, which enhance the
hydrophobicity of proteins and convert SAs to more complex nanoparticles. Taken
together, SAs have been recommended as convenient and suitable scaffolds for
nanoparticle design. Further, SAs are composed of cell bases, which promotes higher
tolerability compared to chemically based nanoparticles.
Advantage of Using Human Serum Albumin as a Drug Delivery Platform
Human serum albumin (HSA) consists of three homologous domains known as I,
II, and III, with multiple hydrophobic subdomains. HSA is responsible for transporting
drugs, hormones and other metabolic substrates; therefore, due to its unique merit, HSA
can serve as a versatile platform to transport hydrophobic as well as hydrophilic drugs
simultaneously.
HSA is an abundant plasma protein in human blood. It is produced by the liver
and has a half-life of 19 days. One of the most desirable advantages of using HSA is the
fact that it can be actively internalized within cancer cells via 60kDa glycoprotein (gp60)
and caveolin-1-mediated transcytosis receptors. Thus, nanoparticles designed from HSA
can benefit from these natural transporting pathways122. In addition, while evidence
shows that the main process responsible for HAS NPs penetration in the tumor site is due
to the enhanced permeability and retention (EPR) effect, and by targeting tumor-derived
secreted proteins (SPARC) for the successful accumulation of HAS NPs in tumor
sites78 123. Furthermore, SPARC proteins are overexpressed by many tumors such as
breast, lung, prostate etc. In short, HSA provides a bioavailable, biocompatible, and
biodegradable platform, with low immunogenicity, low toxicity, and capacity for dual
loading. Thus, HSA is ideal for the development and design of novel nanocarriers.
Utilization of an HSA platform increases the solubility of hydrophobic drugs,
mostly due to the negatively charged surface of HSA, which makes it a highly
water-soluble biomolecule. HAS NPs can form via aggregation and or crosslinking of
HSA molecules and creation of intermolecular disulfide bonds44. In addition,
hydrophobic agents can induce the self-assembly of HSA proteins and make them even
more stable. Albumin-bound paclitaxel NPs (Abraxane®) is an FDA-approved
nanomedicine for metastatic breast cancer, which was able to significantly increase OS
by ten weeks124.
In the present investigation, we aimed to study the development and
characterization of stable HSA-based nanoparticles using simple self-assembly by the
solvent evaporation method. The solvent evaporation method is the most frequently used
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method in nanoparticle preparation. It is less complex and more time-efficient than other
methods, making it promising for manufacturing purposes. Therefore, we hypothesize
that nanoparticle-mediated drug delivery using an HSA basis will effectively improve
drug uptake into tumor cells, enhance anticancer activity, and lower undesirable side
effects.
Use of Natural Small Molecules as Crosslinkers and Stabilizers
Indeed, in forming the perfect NDDS, there is an urgent need to employ and select
pharmaceutical excipients wisely. Pharmaceutical excipients are used to enhance aqueous
solubility, improve long term stability, increase bioavailability, and increase therapeutic
value and other favorable characteristics, while also ensuring the safety of the finished
product. The selection of nanoparticle excipients will determine the physicochemical and
biological fate of designed nanomedicine formulations in in vitro and in vivo models, and
ultimately in patients’ bodies125 126. Therefore, it is necessary to design relatively simple,
yet safe and stable self-assemblies in order to transport therapeutic drugs to the tumor
site. It is also important to be cognizant of toxicity that may result from residual
chemical crosslinking agents. Herein, we decided to choose a natural stabilizing
compound that would exhibit better binding affinity to plasma proteins and biofluids,
while also assisting in efficient penetration to the tumor site, without jeopardizing the
safety of healthy tissues.
Recently, tannic acid (TA, C76H52O46), a natural polyphenol extracted from
different types of plants (e.g. green tea), has gained attention as an additive natural
compound. TA has various beneficial therapeutic properties. It was previously known as
a potent antioxidant, an anti-inflammatory agent, and it has also been used as an
anticancer and chemo-sensitizing agent127 128 129. However, this compound lacked
sufficient potency. Thus, scientists have begun to use TA as a stabilizer and crosslinker in
nanoparticle formation 76 130. The structure of TA has hydroxyl and carboxyl functional
groups, which provide secure binding sites to proteins and DNA 131. It is also a
water-soluble compound with low viscosity (favorable in the formulation procedure) and
an excellent biocompatibility profile. Furthermore, it easily binds to different drugs via
hydrophobic interactions.
Based on these promising characteristics, we determined that using TA as a
stabilizer to develop Human serum albumin-tannic acid nanoparticles (HTA NPs), might
also produce a higher binding affinity of HTA NPs in lung fluids. Thus, HTA NPs will
not only enrich the chemotherapeutic efficiency of loaded drugs, but also decrease
off-target toxicity.
Therefore, human serum albumin nanoplatforms with tannic acid as a stabilizer
(HTA) will have a safer toxicity profile and will overcome previously mentioned
limitations of simple multifunctional nanoparticles. This nanoparticle is speculated to
provide a dual loading platform for co-delivery of the hydrophobic and hydrophilic
drugs, as well as potentiate their synergistic effect on NSCLC.
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This approach efficiently eliminates limitations in multicomplex methods of
nanoparticle synthesis. It also eliminates the need for organic solvents for hydrophobic
drugs and reduces toxicity issues involved in using chemical excipients in nanomedicine
formulations. Indeed, it could revolutionize the development of multidisciplinary
strategies for NSCLC therapy.
Hypothesis and Specific Aims
Despite the establishment of several therapeutic strategies, Lung cancer (LC)
stands as the main source of cancer-related mortality among both males and females in
the United States and worldwide, with the overall 5-year survival rates for advanced
stages with distance metastasis is less than 5% 4. Statistics estimate approximately
228,150newly diagnosed LC cases and 142,670 deaths in the United States in 2019
alone8. Based on the histopathological phenomenon, LC is categorized to small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC). Around 85-90% of the LC
cases fall under the category of NSCLC, roughly 194,000 new NSCLC cases in 2019.
Surgery, radiation, chemotherapy, targeted treatments and immunotherapy—alone
or in combination—are the current options for treating NSCLC. By a considerable
margin, conventional chemotherapy, such as gemcitabine, carboplatin, cisplatin,
paclitaxel and irinotecan, have shown to be the most effective regimens for NSCLC;
however, they have resulted in only modest survival improvements due to limitations
such as chemo-resistance, relapse, cancer recurrence, and intolerable toxicities from high
drug dosage and other adverse effects. Therefore, there is an emerging need for
optimizing and validating new therapeutic strategies to circumvent these problems.
Among other chemotherapeutic agents, Gem has an outstanding profile. Gem is
a pyrimidine nucleoside antimetabolite and has been used widely for different types of
cancer therapy, specifically NSCLC, for decades 29. Gem was able to increase the median
survival rate of NSCLC patients by 20-25% ( 9 months)25 132, however, the main clinical
drawback of Gem therapy is the development of the resistance by NSCLC tumor cells,
either by P-gp-mediated efflux, or other involved pathways133. Currently, there is a
diverse range of clinical trials for Gem in combination with other chemotherapeutic
agents. For instance, a combination of cisplatin with Gem causes a 46% reduction in drug
resistance in tumors (with highly resistant and intermediate level) in comparison to Gem
therapy alone48. However, clinical applications of this type of combination are often
associated with disadvantages due to adverse side effects such as neutropenia,
neuropathy, myelosuppression, and nephrotoxicity. Hence, a combination of Gem with a
sensitizer/anticancer agent having a more favorable safety profile is highly desired. Such
a combination could achieve higher treatment efficacy, procrastinate /eliminate the
development of drug resistance, and reduce side effects and toxicity issues. Therefore, we
selected Gambogic acid (GA) with the chemical formulation of C38H44O8, a natural
compound isolated from the gamboge resin of Garcinia hanburyi tree. Selection of GA
was based on previous studies that have identified GA as a potent apoptosis inducer, an
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anticancer agent and chemo-sensitizer in different types of cancer, and its favorable
safety profile 34 134. However, GA is relatively water insoluble, which increases the in
vivo toxicity. Moreover, traditional delivery of this combinatorial therapy may result in
limited therapeutic efficacy and severe side effects due to unspecific targeting.
Nanomedicine and the development of novel nanocarriers are gaining attention for cancer
therapy. Nanocarriers can efficiently deliver therapeutic drugs to the tumor site,
increasing drug concentration within tumor cells, thereby lowering the total required dose
and significantly reducing side effects. There has been enormous investigation in loading
chemotherapeutic agents in nanoparticles. One of the most successful of these
nanomedicines is Abraxane (albumin bonded paclitaxel), which was approved by the
FDA in 2005 for metastatic breast cancer. Since then, it has gained FDA approval for
other cancer types (e.g. NSCLC, ovarian, and pancreatic cancers).
Furthermore, albumin, the primary component of human serum proteins, is
proven to be an excellent nanocarrier for drug delivery. Albumin is biocompatible,
biodegradable, has low immunogenicity and low toxicity, and it serves as a transporter in
the body85 135. Studies reported that HSA has the ability for dual loading. Furthermore,
another study revealed that GA, a highly hydrophobic chemo-sensitizer agent for
NSCLC, can bind to human serum albumin (HSA) via hydrophobic interactions formed
between the drug molecule and the hydrophobic subdomains of HSA 85 136 137. This
unique platform can create a stable self-assembly with hydrophobic molecules. It has
several advantages, such as the ability to carry multiple, large therapeutic payloads, a
desirable size and zeta potential, surface functionality with the ability to attach to
different targeting ligands (enabling targetability and specificity), and increased water
solubility of hydrophobic molecules. It can also readily bypass RES clearance and take
advantage of the EPR effect 138 85. Furthermore, it also has an excellent drug release
profile and good serum stability 139 121. In the present study, we investigated the
anti-tumor effect of HTA formulation loaded with a GA and Gem (G-G) combination in
in vitro and in vivo systems, using non-small cell lung cancer cell lines and a xenograft
mouse model. The schematic representation for preparation of proposed nanoparticle is
shown in Figure 1-5 . The NP core was composed of HSA, an abundant plasma protein,
and TA, a stabilizer crosslinker. TA is a natural compound and FDA-approved food and
drug additive, which was utilized as a stabilizer and crosslinker in this NP formulation.
Both HSA and TA are biocompatible and biodegradable. Finally, Gem and GA were
loaded by the solvent evaporation method to the HTA NPs, referred to as G-G@HTA
NPs.
Based upon our in silico data, through docking studies, we predicted that GA and
Gem can successfully interact with HSA while, they fit perfectly into the HSA binding
site (with 1195 and 596.40 interact surface and -7.81 and -6.25 kcal/mol estimated free
energy of binding respectively) (Figure 1-6). We computationally docked the chemical
structure of GA into the HSA binding site, revealing that 42 residues on the
conformational structure of HSA interacted with GA and similarly 36 residues interacted
in case of Gem and HSA structure, these data further contributed in preparation of
nanoparticles and determination of the loading capacity ratio of the drugs to the
HSA(w/w).
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Figure 1-5. Schematic representation of the steps involved in HTA NPs loaded
with Gem and GA synthesis.
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Figure 1-6.
Docking gambogic acid and gemcitabine into HSA binding sites.
GA and Gem (shown with green) was docked into the computational binding site of the
human serum albumin (HSA) receptor (shown with blue).
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Altogether, the central hypothesis of my project is that the internalization and
permeability of self-assembled HTA NPs when loaded with combined anticancer agents
(Gem and GA), will improve the therapeutic efficacy of Gem and GA in NSCLC tumor
cells, while also reducing the off-target drug toxicities of conventional NSCLC therapies
involving free drug combinations and single agents (Figure 1-7). Accordingly, with the
objective to test this hypothesis, the following specific aims were proposed:
Aim 1. To Investigate the Interaction of Tannic Acid and Lung Fluid
The purpose of the first specific aim was to test the interaction of tannic acid with
lung fluid proteins, to better understand the delivery aspect and binding affinity of the
formed self-assemblies to NSCLC cells.
Aim 2. To Investigate the Synergistic Anticancer Potential of Gemcitabine and
Gambogic Acid on NSCLC
The purpose of this specific aim was to investigate the elevated anticancer effect
of Gem in combination with GA on NSCLC, as a potent apoptosis inducer and sensitizer.
Furthermore, we examined the synergistic effect of GA with Gem in in vitro assays. We
also studied the sensitization ability of GA on Gem therapy in NSCLC cell lines (A549
and H1299).
Aim 3. Construction and Investigation of the Synergistic Anticancer Ability of
Self-Assembled Human Serum Albumin-Tannic Acid Nanoparticles (HTAs) Loaded
with Combined Anticancer Agents (Gem and GA(G-G)) for NSCLC Therapy
The purpose of the last specific aim was to prepare and characterize HTA NPs
and load them with Gem and GA referred as G-G@HTA. After the process of developing
the G-G@HTA NPs, these NPs were characterized for mean size, polydispersity index
(PDI), zeta potential, binding affinity, FTIR and morphology. Cellular uptake and
elevated anticancer effects of G-G@HTA NPs were examined via in vitro assays. Finally,
the targeting ability, biodistribution, and improved therapeutic efficacy of G-G@HTA
NPs were tested using a xenograft mouse model.
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Figure 1-7.

Schematic representation of overall project strategy for hypothesis.

30

CHAPTER 2. TANNIC ACID-LUNG FLUID ASSEMBLIES PROMOTE
INTERACTION AND DELIVERY OF DRUGS TO LUNG CANCER CELLS1
Introduction
Lung or bronchial cancer is the most lethal cancer in the United States with
234,030 estimated new diagnoses and 154,050 deaths in 20185 140.Chemotherapy is the
most common treatment regimen for lung cancer (LC). Most common therapeutic drugs
for LC treatments are carboplatin, cisplatin, gemcitabine, paclitaxel, and irinotecan. The
efficacy of treatment mostly depends on the mechanism by which the drug is delivered
and the optimum concentration of the drug available in the tumor cells. Conventional
chemotherapy has poor distribution and results in only a limited amount of therapeutic
agent(s) reaching tumor cells, due to lung fluid (LF), a biological barrier that restricts
drug penetration to the lungs. There is a significant amount of research dedicated to the
study of drug penetration to lung tumors. Often, the LF corona is a major determining
factor on how these therapeutic agents/complexes behave in in vivo applications. This is a
growing field of research aimed at understanding drug carrier stability and fate when the
carriers encounter proteins in biofluids. These studies direct the research towards
reducing uncertainties involved in the prediction of the behavior of therapeutic
pharmaceutical nanoformulation in in situ and in vivo, and their application in clinical
trials.
Tannic acid (TA) is a polyphenolic compound and an important form of
water-soluble tannin. It is widely found and commercially extracted from plants such as
tara (Caesalpinia spinosa), gallnuts (oak gall), and Sicilian sumac (Rhus coriaria). TA is a
mixture of galloyl esters and their derivatives, and it is represented with the chemical
formula C76H52O46. TA is a useful diagnostic tool as a dye that is used to stain plasma
membranes, particularly binding most prominently to the margins of tumors. This
suggests its binding and targeting efficiency to cancer cells. TA alone was able to protect
against benzo(a)pyrene-induced LC in rats141. Considering these outcomes as patentable
innovation, there was an invention allowed to develop tannin complexes or mixtures with
TA and pharmaceutical compositions. There is substantial evidence that TA is an
important biocompatible and biodegradable compound commonly used for biomedical
and clinical applications142 143 144 .The abundance of hydroxyl functional groups in TA
can offer increased solubilization, complexation, entrapment, and encapsulation of
therapeutic cargo for slow and sustained release applications. TA has been applied as a
carrier for low molecular weight drugs (paclitaxel, docetaxel, amphotericin B, curcumin,
and rapamycin)145 and biomacromolecules (vaccines, peptides, antibodies, and DNA)146
147 148 149
.Additionally, TA has been known to crystalize various active pharmaceutical
ingredients 150. Pre-clinical evidence has shown that TA has significant anticancer and
chemo-preventive profiles151. However, its application in LC has never been studied. All
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these events suggest that TA-based delivery would enhance delivery of therapeutics and
would therefore have relevance in LC.
Drug carrier interaction with serum proteins, which results in a carrier-protein
corona, is a predictor for in vivo stability and applicability152 153. This behavior is
common in the case of intravenous and oral administration of nanotherapeutics. TA in
wine is passively absorbed by serum proteins and has not shown side effects. Our
ultimate objective is to develop TA as a therapeutic carrier to improve bioavailability and
targetability of active pharmaceuticals applied to treatments for lung cancer. The intent of
this formulation is to apply for nasal or pulmonary delivery. Therefore, in this study, we
aimed to investigate the interaction of TA with LF. The interaction studies were
investigated by fluorescence and Fourier Transform Infrared (FTIR), protein dot,
SDS-PAGE, DLS, and transmission electron microscopy (TEM). The LF protein corona
influence on cellular internalization was examined by fluorescence spectroscopy and flow
cytometry. Improved pharmaceutical efficacy through TA-based assembly was confirmed
by cell proliferation assay
Materials and Methods
Materials
All reagents and chemicals stated below were purchased from Fisher Scientific
(Pittsburgh, PA, USA) or Sigma-Aldrich Co. (St. Louis, MO, USA), unless further
information is presented. Bronchoalveolar lavage fluid of mice (simply termed as LF)
was provided by Dr. Amali Samarasinghe (UTHSC, Memphis, TN, USA) collected under
Institutional Animal Care and Use Committee (IACUC) approved protocol. For this, six
week-old female C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor,
ME, USA), and housed in microisolator cages with alpha-dri bedding and free access to
mouse chow and autoclaved water in a climate-controlled room for acclimatization. At
12–15 weeks of age, mice were euthanized by CO2 asphyxiation and the trachea
surgically cannulated. The diaphragm was incised, and bronchoalveolar lavage performed
with two 1 mL aliquots of sterile phosphate-buffered saline (PBS). Cells were separated
by centrifugation at 600× g for 10 min at 4 °C, and the fluid was stored at −80°C until
use.
TA-LF Complexation
TA and LF interaction leading to self-assembly/complexation was investigated by
analysis of LF protein corona formation on TA molecules. For this, 30 μg of mouse LF
was incubated with various concentrations of TA for 1 h in 2 mL Eppendorf tubes.
According to our previous reports, protein corona formation takes place after 30 min153
152
.The tubes were centrifuged in Sorvall ST 8 Centrifuge at 5000 rpm (Thermo Fisher
Scientific, Suzhou, China) for 2 min to separate any large clumps. This fine TA-LF
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complex suspension was used for all studies. Both TA alone and LF alone were used as
controls, separately.
Fluorescence Spectroscopy
The binding ability of LF protein tryptophan residues with TA was evaluated by
measuring fluorescence quenching using fluorescence spectrometry with a SpectraMax
Plus plate reader (Molecular Devices, Sunnyvale, CA, USA). The fluorescence emission
spectra were recorded between 250 and 400nm (slit at 5nm) at an excitation wavelength
295nm (slit at 2nm). Thirty micrograms of LF in 1 mL PBS buffer in a quartz cuvette was
used for the fluorescence quenching experiment. After running this solution as a control
sample, titration was performed with 5, 10, 15, 20, 25, 30, and 40μg of TA by successive
addition of 1 μL of TA (5 mg/mL). This assay was performed in triplicate.
Fourier Transform Infrared Spectroscopy
Fourier transform infrared (FTIR) spectroscopy was employed to confirm the
presence of LF proteins in TA-LF complexes. Ten microliters of TA-LF complex
solutions were placed on a Diamond/ZnSe Attenuated Total Reflection crystal plate and
air dried, then spectra were acquired using a PerkinElmer Spectrum 100 FTIR
spectrometer (Waltham, MA, USA). The spectra were recorded for these samples and
TA/LF samples (controls for peaks comparison) from 4000 to 650 cm−1 with a resolution
of 4 cm−1. FTIR spectra were presented as an average of 32 scans for all samples.
Protein Density and SDS-PAGE Gel of TA-LF Complexes
Following TA and LF complexation, the TA-LF complex solution was
centrifuged at 1000 rpm (Sorvall ST 8 Centrifuge) to obtain stable TA-LF
self-assemblies. Ten μL of these complex solutions, were transferred onto a nitrocellulose
membrane (Bio Rad, Hercules, CA, USA) and the samples were allowed to diffuse
protein into the membrane and dry at room temperature. Following a rinse with DI water,
the membrane was incubated in 5 mL of 0.25% Coomassie Blue R-250 dye (#20278,
Thermo Fisher Scientific) (50:10:40 v% methanol: glacial acetic acid:DI water). The
nitrocellulose membrane in Coomassie Blue solution was heated in a 1200 W microwave
for 30 s After cooling to room temperature, the dye solution was drained, and the
membrane washed twice with DI water, then destained in 50:10:40 v% methanol: glacial
acetic acid:DI water solution without dye until it displayed a clear background. After a
final rinse with DI water, the blue spot protein-stained membrane was stored in DI water
at room temperature and image captured using a camera. This assay was performed in
triplicate. Similarly, these TA-LF complexes were used for generating SDS-PAGE gels
according to our previous protocol 152.
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Particle Size and Zeta Potential
The intensity-weighted average particle size (nm), particle distribution, and
polydispersity index (PDI) of samples were measured with a dynamic light scattering
method using a Zetasizer instrument (Nano ZS, Malvern Instruments Ltd.,
Worcestershire, UK). To acquire these measurements, 20μL of each sample solution was
added to 1000μL of filtered Milli-Q water and probe sonicated (VirSonic Ultrasonic Cell
Disrupter 100, VirTis, Woburn, MA, USA) for 30 s. Particle size measurements were
performed at 25 °C for 3 min. An average of three readings for each solution was
calculated and recorded. Zeta potential (ζ, mV) of the particles was quantified with laser
Doppler velocimetry using the same instrument. Samples were diluted with PBS and
measured for 30 runs each. Data were recorded as an average of three readings. These
measurements were also acquired in solutions of different pH.
Particle Morphology
The particle size and morphology of TA-LF complexes were examined by using
TEM (JEOL 200EX, JEOL Ltd., Tokyo, Japan). For this investigation, after probe
sonication of the TA-LF complex solution for 30 s, 20 μL of solution was dropped
carefully on the shiny side of the 200-mesh standard TEM grid (#FCF200-CU-SB,
Electron Microscopy Sciences, Hatfield, PA, USA). UranyLess EM Stain solution
(22409, Electron Microscopy Sciences) was used as a positive contrast agent to achieve a
stronger contrast between the background and the nanoparticles. Morphology
examination of TA-LF particles was performed on air-dried grids at 80 kV accelerating
voltage under an advanced microscopy digital camera imaging system (Advanced
Microscopy Techniques, Corp., Woburn, MA, USA).
Cell Culture, Growth, and Condition
The human LC cell lines A549 (carcinoma cell line derived from 58-year-old
male Caucasian, #ATCC® CCL-185™) and H1299 (carcinoma non-small cell LC cell
line derived at the metastatic lymph node from 43-year-old adult, #ATCC®
CRL-5803™), were purchased from American type culture collection (Manassas, VA,
USA). These cell lines were expanded, grown, and used at low passages for experiments.
The expanded cell line aliquots (less than 5–6 passages) were stored frozen in liquid
nitrogen for future usage. The cancer cell lines cultured under sterile condition in
Dulbecco’s Modified Eagle’s medium (DMEM for A549) and Roswell Park Memorial
Institute medium (RPMI for H1299) supplemented with 4.5 g/L of glucose, 10nM of
nonessential amino acids (# 11140076, Gibco, Thermo Fisher Scientific, Grand Island,
NY, USA), 100mM of sodium pyruvate (#11360070, Gibco), 1× antibiotic/antimycotic
(#15240062, Gibco), and 10% heat-inactivated FBS (#10438026 Thermo Fisher). Cells
were maintained in 100mm tissue culture dishes (#83.3902, Sarstedt, Inc., Newton, NC,
USA) as 2D monolayers in a humidified incubator (5% CO2 and 95% air condition) at 37
°C (Thermo Fisher Scientific, Waltham, MA, USA).
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Cellular Uptake
A semi-quantitative cellular uptake assay of TA-LF complexes was examined by
flow cytometry and fluorescence microscopy methods. To allow cellular uptake
quantification, TA-LF assemblies were labeled with coumarin-6 using our previously
reported method 154 46 155. The extent of dye internalized was used to track uptake of
TA-LF self-assemblies into cells. 100 μg of coumarin-6 dye was loaded in 1 mg of
TA-LF self-assembled. In this study, 2 mL of media containing 5×105 cancer cells per
well were seeded in 6-well plates (#83.3920.005, Sarstedt, Inc.) and cells were allowed to
attach to plates overnight, then were dosed with 5 μg coumarin-6 containing TA-LF
particles with different densities of LF for 30 min to 6 h. After the incubation time, cells
were washed twice with PBS and replaced with fresh phenol red-free media to each plate.
The uptake of TA-LF particles was imaged using an EVOS® FL Imaging System
(AMF4300, Life Technologies, Carlsbad, CA, USA) for visual comparison. For
quantitative measurements, the cells were trypsinized, then centrifuged at 1000 rpm for 5
min and resuspended in 2 mL phenol red-free media. About 10,000 cells from these cell
suspensions were used to acquire fluorescence levels using an Accuri C6 flow cytometer
(Accuri Cytometer, Inc., Ann Arbor, MI, USA). The measurements were performed in
triplicate using FL1 channel (488 excitations, Blue lase, 530 ± 15nm, FITC/GFP).
MTS Assay
The drugs (gemcitabine, carboplatin, irinotecan) encapsulated in TA-LF
formulations were prepared following our established protocol 154. Their anticancer
efficacies were evaluated using a colorimetric cell titer 96 aqueous one solution cell
proliferation assay (MTS assay, Promega, Madison, WI, USA). In this study, LC cell
lines (A549 and H1299) were plated at 5×103 cells/well in 96-well flat bottom tissue
culture plates (#83.3924.005, Sarstedt, Inc.) and incubated at 37 °C in a 5% CO2/95% air
atmosphere overnight for attaching to plate. Cells were treated with free drugs
(Gemcitabine, carboplatin, and irinotecan) and equivalent drug-containing TA-LF
formulations. Respective cell lines with no treatment or TA alone were used as controls.
After 48h treatment, 20 μL of MTS reagent solution was added to each well and
incubated for 2 h at 37 °C. Absorbance was measured at 490nm by a Cytation 5 imaging
microplate reader (BioTek, Winooski, VT, USA). Cell proliferation was normalized to
that of cells cultured in medium with no treatment.
Statistical Analysis
All measurements and results generated in this study were presented as mean ±
standard error of mean (SEM). The statistical analysis and significance of data were
assessed using Student’s t-test; significance was set at p < 0.05 with GraphPad 5.03
Prism program (La Jolla, CA, USA).

35

Results and Discussion
Efficient delivery of therapeutics remains the most desirable outcome for treating
LC. However, successful delivery is always compromised by poor penetration, quick
elimination, and poor bioavailability. This phenomenon is partly due to the abundance of
LF, which determines the fate of the drug. Greater interaction with LF may lead to
crosslinking with proteins, and thus a huge foreign particle can develop and be eliminated
by the system. Therapeutic formulations with limited interaction with LF proteins and
unique complexation/self-assembly formation may improve circulation and deep
penetration into lungs. Considering this hypothesis, TA is proposed as a carrier for LC
therapeutics, and thus this study aims to examine its specific interaction with LF. Further,
this study will also explore the possible therapeutic role of drugs encapsulated within
TA-LF self-assemblies.
Fluorescence Binding
First, we tried to delineate the TA-LF complexation process using the
fluorescence (FL) quenching of proteins present in LF that would interact with tannic
acid. The fluorescence of proteins arises from tryptophan residues in proteins156 157. TA
exhibited a dose-dependent fluorescence decay (Figure 2-1a). This is primarily due to
inter/intra-molecular interactions of the hydroxyl groups of TA with the amine groups of
proteins. Such interaction occurs from a complex formation between protein and TA,
which is responsible for quenching of the intrinsic fluorescence of the two tryptophan
residues (Trp-134 and Trp-212).
These data suggest that TA interaction with LF proteins is caused by coating or
protein corona formation. Further, at lower concentrations, TA exhibited a minor change
in fluorescence decay, indicating little interactions, while significant quenching occurs
when TA concentrations employed were 20μg/mL and above.
Fourier Transform Infrared Spectroscopy (FTIR) Spectral Analysis
FTIR spectral analysis allows for a quick and efficient confirmation of TA and LF
proteins by their functional groups (Figure 2-1b). The spectra of TA and TA-LF
complexes displayed characteristic peaks of TA at 3280 cm−1 due to phenolic O–H
stretch of the hydroxyl groups, 1725 and 1697 cm−1 due to C–O stretch of the carboxyl
groups, and 1082 cm−1 due to C–O–C vibrations. The additional absorption bands at
1016, 1066, and 1187 cm−1 are ascribed to the vibrations of substituted benzene rings in
TA and TA-LF. The spectrum of LF alone shows characteristic peaks for the amide I
band at 1655 cm−1 (mainly C–O stretch) and amide II band at 1525 cm−1 (C–N

36

Figure 2-1. Spectral and biological confirmation of TA-LF complex formation.
a) Instant binding and self-assembly/complex formation of LF and TA was measured by
measuring fluorescence (FL) quenching. Representative FL quenching profiles of
30μg/mL LF with increased TA solution (5–40μg) at room temperature (λex = 295nm).
(b) FTIR spectra of TA and TA-LF complexes. Characteristic peaks at 1653 and 1525
cm−1 represent the presence of LF in TA-LF complexes. (c,d) Protein dot and SDSPAGE confirms presence of LF proteins in TA-LF complexes by visual evidence.
Coomassie Blue stains lung fluid protein in TA-LF assemblies but not free tannic acid.
(a,c,d) Data acquired from 3 sets of samples for confirmation. MFI=Mean fluorescence
intensity.
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Stretching and N–H bend) (Figure 2-2). The other peaks at 3290 and 1075 cm−1
correspond to N–H and C–N stretch of the aliphatic amine moiety (Figure 2-2). In the
spectra of the TA-LF complexes, the specific peak at 1653 cm−1 belongs to the amide I
band of LF, while other bands coincide with TA characteristic peaks (Figure 2-1b). The
major amide I peak decreased relatively with increase of TA in TA-LF complexes.
LF Proteins in TA-LF Complexes
Control LF and the TA-LF complex samples show almost equivalent protein stain
with Coomassie Blue on nitrocellulose membranes (Figure 2-1b). There is no strong
signal observed for TA alone samples. To gain better insights of TA-LF complex
formation, we separated supernatant and pellet of TA-LF complexes which are
considered well-dispersed/perfect corona formation and loosely bound corona/aggregates
of corona, respectively. Supernatant TA-LF complexes at TA:LF ratio(s), 30:250, 30:200,
and 30:150 show more protein stain while 30:100 and 30:50 demonstrated almost nil.
This indicates higher TA concentration helping to achieve a better protein corona
(smaller TA-LF complex formation, Figure 2-3) TA-LF complex pellets indicate protein
stain at 30:150, 30:100, and 30:50 reflect due to poor or random corona formation
(Figure 2-4). Altogether, this indicates higher TA promotes smaller TA-LF complexes.
The abundance of LF protein in TA-LF complex samples was observed in SDS-PAGE
gel (Figure 2-1d) due to combination of smaller and bigger complex formation due to LF
corona formation. A similar pattern of protein exists in these samples, which further
confirmed the data shown in Figure 2-1c.
Protein Corona Formation
Protein corona formation is a biological phenomenon that occurs when
nanoparticles incubated with proteins. To investigate such phenomena, DLS analysis
method was employed. TA-LF complexes had particle size less than ~305nm (Figure
2-5a). TA and LF alone showed particle size of 340.8 ± 55.69nm and 338.2 ± 5.64nm,
respectively (Figure 2-3a). A higher amount of TA (250 μg) leads to lower particle size
(105 ± 11.83nm) due to hard protein corona on TA. Lower amounts of TA (50 μg) in TALF generated complexes with a particle size of 304.8 ± 43.64nm. This suggests that TA
concentration plays a major role in determining the globular protein corona formation and
determining particle sizes of complexes resulting from incubation with LF.
TA and LF alone exhibited low negative zeta potentials, −16.03 ± 0.17mV and
−7.68 ± 0.91mV, respectively (Figure 2-3b). When TA content increased in TA-LF
assemblies, their zeta potential values are similar, as seen for LF zeta potential, i.e., −8.55
± 0.20 mV for assembly resulting from 250 μg TA in a TA-LF assembly (Figure 2-5b).
This is evidence that LF proteins are perfectly aligned on the TA core. When TA
concentration is lower in TA-LF assemblies, the resulting zeta potential values lie
between those for TA and LF (Figure 2-5b). This provides support for the hypothesis
that these assemblies might be complexes of irregular formation, depending upon the
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Figure 2-2. FTIR of lung fluid.
Protein characteristics peaks of the amide I band at 1655 cm−1 (mainly C–O stretch) and
amide II band at 1525 cm−1 (C–N stretching and N–H bend) in LF. The other peaks at
3290 and 1075 cm−1 corroborates to N–H and C–N stretch of the aliphatic amine.

Figure 2-3. DLS data for (a) particle size and (b) zeta potential of TA and LF.
Measurements were performed using Zetasizer.
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Figure 2-4. Protein dot assay of supernatant and pellet.
TA-LF complexes were separated by centrifugation at 5,000 rpm and supernatant and
pellet TA-LF complexes were used for protein density probing on nitrocellulose
membrane as mentioned in section above in the manuscript.

Figure 2-5. Physical characterization of TA-LF complexes.
(a) Particle size and (b) zeta potential of TA-LF complexes. Measurements were
performed using Zetasizer. Increasing LF inclusion in TA-LF alters protein corona on TA
and the change in their particle size and zeta potentials. Data presented as mean ± SEM
(n = 3). (c) Representative transmission electron microscopic image of TA-LF selfassemblies. Image was acquired using advanced microscopy digital camera system Print
magnification 160,000×.
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amounts of TA employed. However, it is important to note that there is no positive zeta
potential observed, which indicates that all TA-LF systems are stable, and complexation
does not lead to huge aggregation or precipitation. Additionally, a negative zeta potential
for nanosystem(s) or carrier(s) implies that these are safe for therapeutic applications,
unlike a positive zeta potential for such materials, which induces systemic toxicity.
TEM analysis was conducted to investigate the visual evidence for TA-LF
complex formation and to observe the morphological status of each complex. TA-LF
complexes exhibited a self-assembled spherical shape, about <30nm with aggregations of
<120nm (Figure 2-5c). Such well-defined morphology of TA-LF nanoparticles can be an
indication of effective penetration ability in lungs. Further, this indicates that TA is not
inducing larger aggregates, which often cause elimination from circulation.
The particle sizes of TA-LF assemblies were tested at different pH solutions (6.8,
7, and 7.4) (Figure 2-6a). Interestingly, a significant increase in particle size was noticed
at pH 6.8 (751.33 ± 32.26nm) compared to all other pH measurements. This could be due
to the loosening of proteins from the self-assemblies or protein corona on TA core. Such
dissociation of self-assemblies may offer immediate release of therapeutics which is
helpful in drug delivery. That means at tumor pH (around ~6.8) self-assemblies dissociate
and release drugs for quick response or targeted delivery mechanism. It is also equally
possible that TA is hydrolyzes more at this pH compared to other pH. However, zeta
potentials were all negative for all pH tested (between −15.86 ± 0.76mV and −19.13 ±
0.92mV, Figure 2-6b).
LF Protein Corona Promotes Interaction with LC Cells
It is essential for cancer therapeutic applications that drug carriers be able to
internalize into the cancer cells, and the release the drug in the cytosol, to achieve a
relevant beneficial therapeutic effect.
First, we investigated the uptake of TA-LF complexes by A549 and H1299 LC
cells using fluorescence microscopy. Abundant intracellular distribution of TA-LF
complexes is observed in cells through coumarin-6 labeling (Figure 2-7a). To achieve a
global pattern of uptake of TA-LF complexes, flow cytometry was employed. For this, an
average of 1×104 cells were used to measure fluorescence intensities. An elevated
intensity of green fluorescence was observed in both cell lines with increased amounts of
LF protein in TA-LF self-assemblies used for the experiment (Figure 2-7b). Further, it
was confirmed that this cellular interaction is time dependent (Figure 2-7c). With
increased time of contact, the TA-LF complexes interact more with LC cells, due to the
enhanced adherence of LF on the TA core.
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Figure 2-6. Influence of LF protein corona in TA-LF complexes with change in
pH.
(a) Particle size and (b) zeta potential of TA-LF were measured in different pH of 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer solutions. Data presented
as mean ± SEM (n = 3).
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Figure 2-7.
LF corona promotes cellular uptake of TA-LF complexes.
a) Cellular uptake of dye labeled TA-LF in A549 and H1299 cells. Cells were treated
with coumarin-6 labeled TA-LF (5 μg coumarin-6 equivalent) for 3 h. Representative
fluorescence image was presented. (b) LF corona on TA exhibited enhanced cellular
uptake in A549 and H1299 cells. Coumarin-6 concentration in TA-LF was 5 μg/mL and
incubation time was 3 h. (c) Time-dependent cellular uptake of coumarin-6 labeled
TA-LF complexes. (b,c) FL levels of internalized coumarin-6 labeled TA-LF complexes
were measured using an Accuri C6 Flow Cytometer in the FL1 channel. Data presented
as mean ± SEM (n = 3). Uptake is significance compared to no LF or control cells (* p
< 0.05).
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TA-LF Improves Pharmaceutical Activity in LC Cells
To study the potential enhancement of anticancer activity when encapsulated in
TA-LF assemblies, we employed an MTS assay against two LC cell lines. This assay
measures viability of the cancer cells based on mitochondrial respiratory activity. There
is no effect on A549 and H1299 cells when treated with free TA-LF complexes (without
drug) (Figure 2-8), red color lines). A clear dose-dependent effect was observed with
free pharmaceutical drugs (Gemcitabine, carboplatin, and irinotecan) against cancer cells
(Figure 2-8), green color lines). TA-LF complexes showed more significant
growth-inhibiting effects than free drugs (Figure 2-8), blue color lines). This indicates
that TA-LF assemblies promote interaction and delivery of drug(s) to the cells tested. In
all drug-encapsulated TA-LF assemblies, there was at least 2–2.5 fold reduction in their
IC50 values compared to free drugs (Figure 2-8c).
An effective chemotherapy not only lowers systemic toxicity, but also lowers the
therapeutic dose. This study supports the hypothesis that TA-LF can be implemented as
an efficient drug carrier (Figure 2-9). The developed method may overcome
conventional chemotherapy and its associated drawbacks such as modest benefit and drug
resistance. Lately, nanomedicine (for example, AbraxaneTM, a paclitaxel self-assembled
human serum albumin formulation) represents a universal drug delivery platform for the
treatment of LC, which makes chemotherapeutic drugs more efficient in treatment
regimens. Likewise, our TA-based drug formulations might serve as a better therapeutic
modality for LC. Our future investigation on these formulations will include studies
regarding superior molecular mechanisms and pre-clinical animal studies.
Conclusions
Overall, this investigation revealed a naturally occurring water-soluble
polyphenolic drug carrier and its interaction with LF proteins. The study demonstrated
that TA exhibits superior and well-defined protein corona formation. This was
demonstrated by particle size, zeta potential, morphology, cellular internalization, and
anticancer activity assays. Further, the results can be extrapolated to physiological
relevance of the adsorption of LF and reduction of surface tension. Therefore, TA may be
proposed as a promising carrier for future research into drug delivery application.
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Figure 2-8. TA-LF complexes promote delivery of encapsulated therapeutic drugs
to LC cells.
MTS assay of drug-encapsulated TA-LF complexes against a) A540 and (b) H1299 LC
cells. Cells (5×103) were seeded in a 96-well plate and left overnight for cell attachment
to the plate, the cells were treated with indicated concentrations of Gemcitabine,
carboplatin, and irinotecan and their respective drug encapsulated TA-LF complexes for
48h. Cell viability was determined using MTS assay. The data were presented in the form
of line graphs as percent viable cells compared to untreated cells in medium. Data
presented as mean ± SEM (each treatment, n = 6). Cytotoxicity of TA-LF-drug
formulations were significant compared to free drugs (* p < 0.05). (c) IC50 values of
drug vs. drug-encapsulated TA-LF assemblies presented as heat map. IC50 values were
calculated using GraphPad software (La Jolla, CA, USA).
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Figure 2-9. Schematic representation of LF corona influencing delivery of TA-LF
assemblies to LC cells.
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CHAPTER 3.

GAMBOGIC ACID SENSITIZE NON-SMALL CELL LUNG
CANCER CELLS TO GEMCITABINE THERAPY
Introduction

In spite of several currently approved therapies, lung cancer (LC) remains a
leading cause of cancer-related mortality, the overall 5-year survival rate is as low as
15%, with approximately 142,670 estimated deaths in the United States in 2019 4. Based
on histopathology158, LC is categorized as either small cell lung cancer (SCLC) or nonsmall cell lung cancer (NSCLC).2 Around 85-90% of the LC cases fall under the
category of NSCLC.5 Surgery, radiation, chemotherapy, targeted treatments and
immunotherapy (alone or in combination) are the current therapeutic options for NSCLC.
159
By the time of the diagnosis most patients (~ 65%) already have advanced stage
disease and have developed distant metastases160.
The conventional chemotherapeutic agents such as Gem, carboplatin, cisplatin,
paclitaxel and irinotecan offer the most effective and promising regimens161 162.
Unfortunately, in most cases these chemotherapeutic agents only provide good initial
responses, with patients eventually developing rapid drug resistance. The resulting
modest survival improvements are due to issues such as recurring cancer relapse,
intolerable toxicities as a result of increase in the drug dosage, and severe side effects 48
163
. Drug resistance is a major challenge for NSCLC therapy, and the main challenge is to
improve the outcome of these group of chemotherapeutics, to preserve their potency in
patients who developed acquired or innate chemoresistance, and to avoid cancer
recurrence and relapse164165. Therefore, management of NSCLC demands a multimodal
approach and there is an imminent need for optimization and validation of new
therapeutic strategies to circumvent this problem.
Gem, a pyrimidine nucleoside antimetabolite, has been widely used for different
types of cancer therapy. It is well known as the most commonly used chemotherapeutic
agent in lung cancer for decades with favorable results29 32. Gem has a relatively low
toxicity profile and is known to increase the median survival rate by 20-25% 166.
Therefore, Gem has improved the median overall survival rate by 4-9 months, but it is
not exempted from chemoresistance which hinders the maximum capacity of Gem
therapy. In a large study investigating 3,042 NSCLC patient tumors, the researchers
found that 72% had extreme or intermediate resistance against Gem167. Intrinsic
resistance is caused by metabolic regulation of Gem uptake and other anti- apoptotic
pathways, and is mainly due to drug transporters and metabolic enzymes which lead to a
decrease in its cellular uptake 34 168. There are multiple ongoing clinical trials aimed to
enhance outcomes of Gem therapy and conquer these pitfalls, by combining it with other
therapeutic agents. For instance, combination of cisplatin (platinum-based antineoplastic)
with Gem led to a 46% reduction in drug resistance48. However, combinatorial
approaches of this type often encounter obstacles due to adverse side effects such as
neutropenia, neuropathy, myelosuppression and nephrotoxicity. Despite several attempts
at pursuing different drug combinations with Gem, there are still no convincing
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results169. Hence, the combination of Gem with a chemo-sensitizer/anticancer natural
compound that has distinct molecular mechanisms and a favorable safety profile could be
considered a promising therapeutic strategy. Such a combination would strive to achieve
higher efficacy of treatment, eliminating drug resistance development, and yet reducing
the side effects and toxicity issues. In this regard, we selected Gambogic acid (GA,
chemical formula; C38H44O8), GA is a xanthonoid derived from the resin of Garcinia
hanburyi tree170 171. Therefore, it has a plentiful and cost-efficient supply together.
Previous reports have identified GA as a potent apoptosis inducer, an anticancer agent,
and inhibitor of tumor growth. In addition, GA has a good safety profile and high
therapeutic index in various diseases, including different type of cancers. Furthermore,
unlike other natural anticancer agent which failed to gain favor due to lack of potency,
GA has shown to be effective at lower concentrations (nM range)64 62 . GA is known to
have a chemo-sensitization effect on various cancer types ,for instance, it was shown that
GA has sensitization effects on doxorubicin therapy for resistant breast cancer by
inhibiting P-glycoprotein and suppressing survivin expression 70 172 173, Further studies
showed that GA has apoptotic effects on cancer cells by modulating different signaling
pathway such as MAPK/ERK, PI3K/AKT and NF-κB174 175 176 177. Therefore, GA has
gain attention as an anticancer agent to be used for combination therapy. Table 3-1 lists
combination of GA with different chemotherapeutic agents in various cancer type. In
addition to the number of studies about the anticancer inhibitory effect of GA on lung
cancer, a phase IIa clinical trials conducted on GA administered as single agents for
cancer therapy.66 The results of a randomized and multicancer clinical study of GA
therapy for advanced malignant NSCLC, colon and renal tumors demonstrated promising
antitumor efficacy with a good safety profile. Taken together, GA has gained attention as
a desirable candidate for combination therapy in recent decade (Table 3-1). For more
details on GA mechanism of action please refer to introduction chapter.
Therefore, in this study we aimed to investigate the elevated anticancer effect of
Gem in combination with GA on NSCLC as a potent apoptosis inducer and sensitizer.
Furthermore, we examine the synergistic effect of GA with Gem in in vitro assays. We
speculated that GA would sensitize NSCLC tumor cells to Gem therapy by inhibiting the
expression of ribonucleotide reductase (RR) enzyme subunit 2(RRM2). We are confident
that, this research findings, not only enhances the knowledge of NSCLC therapy, but also
implements a theoretical base for the future clinical administration of GA for patients
with NSCLC.
Methods
Chemicals and Reagents
Gambogic acid was purchased from Apex bio (Houston, TX, USA) and dissolved
in in dimethyl sulfoxide (DMSO) and restored in -20ºC and diluted further for usage,
where DMSO was less than 0.1% in the final dilutions. Gem was purchased from Fisher
Scientific (Waltham, MA, USA), and dissolved in sterile PBS. All the other reagents,
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Table 3-1.
Classification of combination therapy with Gambogic acid (GA) and
other anticancer agents tested in different cancer types.
Combined
anticancer
agent
Docetaxel

Cancer type

Combination
type

Breast Cancer

Sensitization

Gastric cancer

-

Gastrointestinal
cancer
Pancreatic
cancer

Synergistic

Heparinquercetin
Cisplatin

Breast cancer

Synergistic

NSCLC

Synergistic

5-fluorouracil

Colorectal
cancer

Synergistic

Retinoic acid
chlorochalcone

Osteosarcoma
Breast cancer

Synergistic
Synergistic

Vorinostat

Neuroblastoma

Synergistic

Imatinib

Myeloid
leukemia

Synergistic

Irinotecan

Liver cancer

Synergistic

Gefitinib

NSCLC

Synergistic

Tandutinib

Meningiomas

-

Chloroquine

Synergistic
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Mechanism of
action

Ref.

Inhibiting P-gp,
post translational
proteasome
Survivin
inhibition
β-tubulin III, tau
and Survivin
Accumulation of
reactive oxygen
species
Inhibiting P-gp

178

Downregulating
MRP2 and LRP
expression
P53, Survivin and
thymidylate
synthase (TS)
Increased
apoptosis

182

JNK-IRE1mTORC1
Inducing
Proteasome
Inhibition and
CaspaseDependent BcrAbl
Downregulation
ERK and p38
MAPK activation
ERK and p38
MAPK activation
Suppressed the
VEGFA-induced
PDGFRβ tyrosine
phosphorylation

186

179
180
181

73

183

184
185

187

188
189
174

Table 3-1.
Combined
anticancer
agent

(Continued).
Cancer
type

Combination
type

Mechanism of action

Ref.

Breast

Sensitization

190

Ovarian
cancer

Sensitization

Inhibiting P-gp &
Survivin
Accumulation of
reactive oxygen
species

Pancreatic
cancer

Sensitization

63

Bladder
cancer

Sensitization

Ribonucleotide
reductase subunit-M2
(RRM2)
Downregulation of
enhancer of Zeste
homologue 2 (EZH2)
expression

Human
epithelial
cancer

Synergistic

Proteasome Inhibition
and reactive oxygen
species generation

Oral
squamous
cell
carcinoma
Renal cell
carcinoma

Synergistic

NF-kappa B inhibition

Doxorubicin

Gemcitabine

Methyl
Jasmonate

Verapamil

Celastrol
Sunitinib

191

192

193

194

Synergistic
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NF-kappa B inhibition

195

solvents, chemicals, and cell culture plastics were obtained from Fisher Scientific
(Pittsburgh, PA, USA) and Sigma–Aldrich Co. (St. Louis, MO, USA), unless otherwise
stated.
Cell Lines and Culture Conditions
Human NSCLC lung adenocarcinoma (H1299 and A549), human lung bronchial
epithelial (BEAS-2B), and human umbilical vein endothelial cells (HUVEC) cells were
obtained from American Type Culture Collection, (ATCC, Manassas, VA, USA) and
maintained as described earlier196. Briefly, A549 cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) and H1299 was cultured in Roswell Park Memorial
Institute medium (RPMI-1640) Gibco, Thermo Fisher Scientific, Grand Island, NY,
USA), Beas-2B was cultured in bronchial epithelial cell growth medium (BEGM), and
HUVEC was cultured in endothelial cell growth medium-2 (EGMTM-2) (Lonza,
Morristown, NJ, USA), all medias contained 10% fetal bovine serum (FBS) and 1%
(w/v) penicillin–streptomycin (Gibco, Thermo Fisher Scientific)) and they were
incubated at 37 °C in a humidified atmosphere with 5 % CO2 (Thermo Fisher Scientific,
Waltham, MA, USA). All cells were regularly monitored for their typical morphology
and contamination under the microscope.
Cell Viability Assay
The MTT assay was performed to detect cell viability following treatment with
free Gambogic acid (GA), Gem, and the combination of GA and Gem in NSCLC cells.
While the effect of GA and Gem alone were also investigated in normal human lung
bronchial epithelial cells (Beas-2B). Cells (0.5×103) were seeded into 96-well culture
plates and left for overnight incubation (to attach to the plates) at 37 °C and 5% CO2
treated with varying concentrations of GA alone (25, 50, 100, 200, 400nM) and (25, 50,
100, 200nM) of Gem alone as well as the combination of both GA+Gem for 48h. Every
treatment was performed in triplicate per experiment, and each experiment performed in
triplicates. Then, 20 μL MTT solution(5mg/ml) was added to 100 μL of the culture
medium (per well), and incubated for 2-4 h at 37 °C. The culture medium containing
MTT solution was discarded and 100 μL DMSO solution was added into the wells that
were further incubated for 15 min at RT while shaking. After this step, the absorbance
was measured using a microplate reader (Cytation™ 5, BioTek Instruments, Winooski,
VT, USA) at 490nm according to the manufacturer’s instructions197 63. The IC50
calculation was performed using GraphPad Prism 6.07 software. The combination index
(CI) was calculated using the Chou–Talalay method198:






 ൌ ቀቁ  ቀቁ  ቀ ቁ
Where Ds1 and Ds2 represent the IC50 of GA and Gem respectively, while, Dc1
and Dc2 are the IC50 values of the drugs applied in combination. (CI< 0.9, synergism,
0.9-1.1, additive effect, >1.1 antagonism).
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Colony Formation Assay
Approximately 300-400 (per well) of A549 and H1299 cells were seeded into 12
well plates for 24h and then treated with/without 25 and 50nM of GA and 25 and 50nM
of Gem as well as the combination of both drugs with respective concentrations for 15
days, and the drug-containing medium was renewed every 3 days. After 15 days of
incubation, formed colonies were fixed with pure cold methanol and stained with 0.05%
crystal violet at room temperature186. Images of the colonies were obtained using a
ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA). All colonies were
counted manually using the NIH ImageJ software freely available on the web (www.
imagej.nih.gov/ij/).
Migration Assay
Cell migration assays were performed in Corning’s 96-well Boyden chambers
(8μm) plates containing polycarbonate membrane as per manufacturer’s instructions.
Briefly, cells were subjected to overnight starvation (by culturing in serum-free medium)
then starved cells (0.5×105 cells/well) were seeded in upper chambers of the plate
containing serum-free culture medium and treatments 100nM and 200nM of GA, and
100nM and 200nM of Gem (separately along with varying combination ratios equivalent
to each single drug) for 18-24 h. Cells without treatment served as controls. Cells were
allowed to migrate from upper chambers with serum free medium towards lower
chambers with complete medium containing 10% FBS. The migrated cells were fixed
with cold 4% paraformaldehyde in PBS for 30 min followed by rinsing with PBS and
then stained with crystal violet for 45 min. Cells in the upper chamber were completely
removed using cotton swabs199 200. The experiments were performed in triplicate and
three random fields were imaged from replicate wells using a Keyence microscope
BZ-X800(Itasca, IL, USA), and the number of cells that had migrated quantified using
ImageJ software.
Cell Invasion Assay
The ability of cells to invade were evaluated using BioCoat Matrigel Invasion
Chambers (BD Biosciences, Bedford, MA, USA) that were coated with matrix
membrane. After starvation of mentioned NSCLC cell lines, 3.5×104 cells per well, were
seeded in the upper chamber of the trans-well plate, containing serum free medium. Cells
were left for adhesion. After 24h they were subjected to treatment with (100 and 200nM)
GA and (100nM and 200nM) Gem alone and equivalent combinatorial doses of both
drugs for 24-36h, cells without treatment served as controls201 202. NSCLC cells which
invaded to the lower chamber were fixed, stained and subjected to the Keyence
microscope, this experiment was done in triplicate.
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Rhodamine-123 Efflux Assay
To study the effect of GA on Gem accumulation inside the cells and its
sensitization activity, the Rhodamine-123 (RH123) accumulation assay was employed.
For this purpose, 0.5×106 /well of A549 and H1299 cells were cultured in a 6-well plate
and left overnight to adhere to the plate and grow. The next day, cells were treated with
(100 and 200nm) of GA and 100nM of Gem and the equivalent combinatorial dosage.
After 24h, 2.62mM of RH123 was added to each well and cells were placed back into the
CO2 incubator for 30 min following previously an established method 203 130. Cells were
then rinsed twice with sterile PBS, in order to wash any undesirable RH123 dye adhering
to the cell surface. Next, the medium was replaced by fresh phenol red-free medium and
subjected to imaging using an EVOS® FL Imaging System (AMF4300, Life
Technologies, Carlsbad, CA, USA) for qualitative observation. After that, cells were
trypsinzed and collected in phenol red-free medium and subjected to quantitative analysis
by using the NovoCyte Flow Cytometer (ACEA NovoCyte® 1000, ACEA Biosciences,
Inc. San Diego, Ca, USA) in FITC channel (fluorescence measurements at λex: 485nm
and λem: 520nm) to measure the mean intensity fluorescence of RH123 dye that was
internalized by the cells204.
Cell Cycle Assay
Approximately 0.5×106 cells (A549 and H1299) were seeded into six-well plates
for culture overnight, they were then treated with varying combinations of GA (100 and
200nM) and Gem (100 and 200nM), and the combination of both drugs for 24h. After
which cells were washed with PBS and collected by centrifugation at 1400rpm for 5 min
and fixed with 70% pure ethanol and kept at least for 48h at -20 °C. Cells were washed
with PBS, and incubated with propidium iodide (PI) solution, FxCycle™PI/RNase
Staining Solution at 37 °C for 1h in the dark following manufacturer’s instructions,
followed by analysis using a Flow cytometer on BL4 channel205. Cell cycle distribution
and the different cell cycle phase data were analyzed by the ModFit software (Verity
Software House, USA).
Apoptosis Detection
The dead cell apoptosis kit with Annexin V Alexa Fluor™ 488 & Propidium
Iodide (PI) Kit (Thermo Fisher Scientific, Pittsburgh, PA, USA) were used to detect
apoptosis by following manufactures instruction and using fluorescence-activated cell
sorting (FACS) machine for analysis. A549 and H1299 cells (5×105 cells) were plated
onto 6 well plate and cultured overnight, followed by incubation with GA (200nM) and
Gem (200nM) simultaneously and also separately for 48h. The cells were harvested and
washed twice in cold PBS, and pelleted by centrifugation at 500 g for 10 min. They were
then resuspended at 106 cells/100 μL in 1X annexin-binding buffer. Stained with 5 μL
Alexa Fluor® 488 annexin V reagent and 1 μL 100 μg/mL PI, for each 100 μL of cell
suspension and incubated in the dark for 15 min at room temperature190 199. They were
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then mixed gently with 400 μL of binding buffer and kept on ice while immediately
processing them with a Bio-Rad ZE5 FACS flow cytometer (Bio-Rad Laboratories,
Hercules, CA, USA).
Western Blotting
Protein extractions from A549 cells treated with different concentrations of
400nM GA and 200nM Gem, and equivalent combination of these two agents, were
performed using standard protocols as previously reported 206 175. For the western blotting
assay, equal amounts of total cellular protein (40μg) were denatured in sample lysis
buffer and subjected to (4-20%) SDS–PAGE. Proteins were transferred from gel to a
nitrocellulose membrane using the trans-blot electrophoretic transfer cell containing Tris
glycine buffer, pH 8.3, and methanol, the transfer procedure was performed 0–4 ◦C for
150 min at 55 V (400 mA). For blocking purposes 3% BSA was used for 1h at RT.
Membranes were incubated with primary antibody with 2%BSA in PBST. Treated cell
lysates were probed by overnight incubation at 4 ◦C on a rocker with the following
primary antibodies:- cleaved caspase 3(#9665), Bcl-2 (#2872), Bak (#3814), Bax
(#2772), RRM2(#65939) and β-Actin (#4970) (Cell Signaling Technologies, Danvers,
MA, USA). Next, membranes were washed three times with PBST (each time for 5min)
and incubated with respective secondary antibodies for 45min. Finally, the blots were
subjected to immunoreactive proteins on nitrocellulose membrane using Bio-Rad ECL
Western Blotting Substrate Solution (Bio-Rad Laboratories, Hercules, CA, USA) 203 129.
Blots were imaged using a Bio-Rad computer-based gel imaging instrument and
analyzed using ImageLabTM software (Bio-Rad Laboratories, Hercules, CA, USA).
Angiogenesis Assay
For examining in vitro angiogenesis, the tube formation ability of HUVEC cells
were assessed in presence and absence of the treatments. HUVECs with passages number
less than five, were seeded in pre-coated flat-bottomed 96-well plates with Matrigel
(Corning, NY, USA) at 1×104 cells/well. After incubation for 4 h with the medium
containing different concentrations of treatment (200nM GA and 200nM Gem, and
equivalent combination of these two agent), HUVEC tube formation were evaluated by
phase-contrast at 10X magnification and photographed by using the EVOS® FL Imaging
System. The length of tubules was assayed inside 2 × 2 square area at the center of each
well207 128. Each experiment was repeated in triplicate.
Statistical Analysis
The GraphPad Prism (GraphPad Software, Inc, La Jolla, CA, USA) software was
used for statistical analysis. Data was presented as means ± SD, and the Student’s t- test
was used to calculate P-values. A p value ≤ 0.05 was considered statistically significant.
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Results
GA and Gem Synergistically Reduce the Growth of NSCLC
The inhibitory effect of GA and Gem on NSCLC cells proliferation was examined
by MTT assay. The MTT assay results, showed that low doses (100-400nM) of GA had
no significant effect on the viability of A549, H1299 and BEAS-2B (Figure 3-1) cell
lines, while cell viability was dose-dependently inhibited at combinatorial doses of GA
with Gem. (Figure 3-2).
We further calculated the combination index (CI) using the Chou–Talalay
method. As displayed in Figure 3-3. the combination of GA and Gem showed a
synergetic effect (CI< 1) in both A549 and H1299 cells. Moreover, as shown in the
heatmap (Figure 3-3), CI values obtained at higher concentration were lower, indicating
more of a synergistic effect on cells. Accordingly, the half maximal inhibitory
concentration (IC50) values after treatment with Ga and Gem in combination were
substantially lower than those obtained after treatment with each single agent.
Furthermore, the ability of NSCLC to form colonies in presence of the Gem and
Ga treatments were examined via colony formation assay. The number of colonies
formed were larger and more prevalent in control wells, while opposite results were
observed in the drug-treated groups (Figure 3-4) indicated that the colony formation
ability of NSCLC cells was significantly reduced by GA and Gem and had a more
pronounced effect when treated with higher combinatorial doses compared with the
single drugs (p < 0.01).
GA and Gem Combination Reduced Permeability P-gp Activity in NSCLC
Rhodamin123 is a fluorescent dye and also a P‐gp substrate208. Therefore, it is a
common indicator to evaluate the ability of drug efflux by P‐gp transporters. To
determine the effect of GA on P‐gp efflux activity and its capability to act as a P-gp
inhibitor and act as a chemo-sensitization agent, A549 and H1299 cells were exposed to
different concentrations of GA and Gem (alone and in combination). In this case the
higher accumulation of RH123 indicates lower P-gp expression. As shown in (Figure
3-5), cells pretreated with GA showed higher RH123 accumulation in comparison with
cells without GA treatment. Intracellular RH123 accumulation in NSCLC cells was dose‐
dependent, as higher GA concentrations showed higher RH123 accumulation, while
lower accumulation was observed with Gem treatment. This may be due to the higher
expression of P-gp, which suggest that GA has an inhibitory effect on P-gp efflux activity
that resulted in the higher fluoresce inside cells. This result signifies the
chemo-sensitization ability of GA on NSCLC and shows that GA prevents the RH123/
Gem efflux from cancer cells, and potentially contributing to a lower probability of drug
resistance occurrence.
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Figure 3-1. Inhibitory effect of GA and Gem on cell viability of NSCLC cells
(A549 and H1299) and on normal bronchial epithelium (BEAS-2B).
(a) GA alone was also tested on A549 and H1299 NSCLC. (b) Gem and GA alone was
tested on normal bronchial epithelium BEAS-2B cells.

56

Figure 3-2. Inhibitory effect of GA and Gem combination on the cell viability of
NSCLC cells.
Cell viability was assessed by MTT assay. Cells were incubated with different
concentration of GA and Gem as single drugs and in combination for 48h. on two
NSCLC cell lines (A549 and H1299).
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Figure 3-3. Heat map of combination index.
CI values calculated using Chou and Talalay method for different concentration ratio of
Gem and GA on A549 and H1299 NSCLC. Values represent the mean ± SEM from three
independent experiments.
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Figure 3-4. Inhibitory effect of GA and Gem combination on the colony formation
of NSCLC cells.
Colony Formation capability of NSCLC were analyzed for the above-mentioned
concentration for 14 days. (a) representative images and (b) graphical representation of
quantitative data analyzed with ImageJ; untreated cells were taken as control (100%).
Values represent the mean ± SEM from three independent experiments; The significance
level was * p < 0.05.
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Figure 3-5. Effect of GA on intracellular Rho123 accumulation in A549 and
H1299 NSCLC cells.
Cells were incubated with medium containing 2.62mM Rho123 pretreated with GA and
Gem with the respective combination dosage for 48h and without pretreatment. After
30min, mean fluorescent intensity (MFI) associated with intracellular Rho123
accumulation was assessed. (a) representative image, (b) A graphical representation of
quantitative data analyzed by flow cytometry. Each point represents the mean ± SD from
four experiments. Values represent the mean ± SEM from three independent
experiments; *p < 0.05, **p < 0.01.
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Combination of GA and Gem Promotes the Suppression of the Migration and
Invasive Ability of NSCLC Cells
The migration and invasion of NSCLC cells plays a crucial role in metastasis. To
evaluate the effect of our drugs on the migration/invasion of H1299 and A549, Boyden
chamber and Matrigel coated plates were used respectively. The number of cells that
migrated (Figure 3-6) and invaded (Figure 3-7) when treated with a combination of GA
and Gem was markedly lower than that of control, as well as the GA and Gem alone.
These results indicated that the combination of GA and Gem significantly inhibited the
migration and invasion of the H1299 and A549 cells.
Combined GA and Gem Treatment Induces Significant Apoptosis in NSCLC
Cell cycle assay was employed to investigate the GA and gem ability to arrest the
NSCLC cells which would lead to apoptosis induction, as well. The cell cycle analysis
revealed that GA arrest cells and promotes S/G2 progression, Gem treatment also arrest
cells in S phase. Next, we investigated whether the synergism between GA and Gem was
related to their combined effect on cell cycle distribution. As shown in (Figure 3-8),
combined treatment significantly increased the apoptotic cell population in the cell cycle
process compared to treatment with either single agent, in both A549 and H1299 cells.
Albeit, the contributions of cell cycle checkpoints and their regulatory effects in a
synergistic manner are mainly unknown. On the other hand, it is well documented that
apoptosis, or the process of programmed cell death is a very important aspect for
maintaining tissue homeostasis. Therefore, further dissection of the cell cycle results was
necessary. Apoptosis is truly differentiated from necrosis, or accidental cell death, by
distinctive morphological changes in conjunction with biochemical changes, as illustrated
by specific nuclear and cytoplasmic properties, and loss of membrane alignments and
asymmetry. Since transference of phosphatidylserine protein (PS) to the outer surface of
the cell membrane is one of the primary features of apoptosis, thus in order to distinguish
the early or late apoptotic cells, the Annexin-V/ PI double staining assay was employed.
Additionally, dual staining with PI allows differentiation of early apoptotic cells
with undisturbed membranes (positive Annexin V and negative PI) from late
apoptotic/necrotic cells with permeable membranes (positive Annexin V and positive PI)
and normal cells (negative Annexin V and negative PI). The Annexin-V- Alexa Fluor /PI
dual staining assay indicated that GA induced a decrease in the percentage of live cells
(bottom left) with a concomitant increase in the percentage of early apoptotic cells (upper
left) and late apoptotic cells (upper right) as compared to untreated cells, in a dosedependent manner (Figure 3-9). GA+Gem cotreatment significantly induced
approximately 6% and 18 % of early and late apoptotic cells respectively). Our result
showed that the expression level of the pro-survival and anti-apoptotic protein (BCL-2)
was significantly reduced with the combination treatment compared to single GA and the
control, and lower than Gem treatment alone. Correspondingly, the expression level of
pro-apoptosis and anti-survival protein (BAK), cleaved PARP, and cleaved caspase 3 was
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Figure 3-6. GA and Gem inhibited cell migration abilities in vitro.
A549 and H1299 cells were incubated with either GA and gem or in combination.
Migration ability was analyzed using a Transwell assay (a) A549, H1299 migration
images, (b) A graphical representation of quantitative data showing the number of
migrated cells. The data were analyzed by ImageJ software. Values represent the mean ±
SEM from three independent experiments; *p < 0.05, **p < 0.01.

62

Figure 3-7. GA and Gem inhibited cell invasion and adhesion abilities in vitro.
A549 and H1299 cells were incubated with either GA and gem or in combination. The
cell invasion abilities were analyzed using a Boyden chamber assay (a) A549 and H1299
invasion images. (b) A graphical representation of quantitative data showing the number
of invaded cells. The data were analyzed by ImageJ software. Values represent the mean
± SEM from three independent experiments; *p < 0.05, **p < 0.01.
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Figure 3-8. Effect of GA and Gem on cell cycle induction in NSCLC analyzed by flow cytometry.
GA and Gem combination increased the apoptosis population on A549 cells, after 24hr treatment incubation for cell cycle analysis.
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Figure 3-9. Effect of GA and Gem on apoptosis induction in NSCLC analyzed by
flow cytometry and western blotting.
A549 and H1299 cells were incubated with GA and Gem and respective combination
concentrations of GA+ Gem for 48h. The x-axis shows Annexin V-FITC staining and yaxis indicates Propidium iodide staining; Lower left (LL) quadrant: viable cells; lower
right (LR) quadrant: early apoptotic cells; upper left (UL) quadrant: necrotic cells, upper
right (UR) quadrant: late apoptotic cells. (b) Western blotting was performed on protein
extractions from A549 cells treated with GA and gem and their combination, using
standard protocols as previously reported. G+G= Combination of Ga and Gem, ClPARP= cleaved PARP and Cl- cleaved= cleaved caspase 3, β-actin was probed for as
internal loading control.
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effectively increased following Gem treatment and GA+GEM cotreatment. The changes
in expression levels were more dramatic for the combination group suggesting that the
induced levels of apoptosis were more prominent compared to single drug treatment.
Next, in order to investigate the effect of these treatments on ribonucleotide reductase
enzyme at the cellular level, we probed the specific RRM2 antibody on the immunoblots.
Interestingly, the expression level of the RRM2 in the presence of Gem alone increases,
but when combined with GA the expression of this protein is downregulated. Suggesting
that GA synergistically inhibits the expression of RRM2 when combined with Gem, and
therefore contributing to Gem resistance reversal. All these considered, the superior
anticancer activity of GA combined with Gem can be confirmed (Figure 3-9).
Combination of GA and Gem Inhibit Tube Formation in HUVEC Cells
The effect of GA and Gem, either as monotherapy or in combination, was
assessed for their ability to inhibit tube formation assays using a HUVEC line209 .
Suppressing the angiogenesis and causing damage to the tumor vascular network, leads to
the inhibition of tumor growth by abducting e supply of oxygen and nutrients. Herein,
with treatment of 200nm GA, 200nm Gem, and their respective combination (GA +
Gem), total master segments length was reduced by 33%,71% and 97% (p < 0.0001)
respectively, compared to the vehicle control (Figure 3-10). Combining these two
compounds achieved the highest inhibition (97%) compared to single drug and the
difference was statistically significant (p < 0.0001).
Discussion
Lung cancer in general including NSCLC has a very poor prognosis and a record
of low therapeutic achievements in recent years. Hence, there is an ongoing, intensive
search for better treatment approaches to minimize the development of chemo-resistance
and its deleterious consequences. GA, a caged xanthone natural compound, is known for
its potent anticancer properties, and to date a couple of studies have already shown the
anticancer effect of GA on NSCLC 176 182 177. However, GA’s chemo-sensitization effect
on Gem therapy in NSCLC has not been examined, therefore in this present study we
further investigated this aspect in order to provide a potential opportunity to overcome
Gem resistance limitations.
In this study, we observed an enhanced anticancer effect of GA+Gem
combination on NSCLC. We demonstrated that the combination of GA and Gem
resulted in synergistic growth inhibition of A549 and H1299 cells, suggesting that GA
could serve as a chemo-sensitizer for Gem therapy on NSCLC, chemo-sensitization effect
of GA observed in our studies concurs with findings from previous investigation with GA
and other chemotherapeutic agents such as doxorubicin and 5- fluorouracil on ovarian
cancer and colorectal respectively 191 183. Many more that reported synergistic anticancer
effect of GA with other chemotherapeutic agents210 211 . Furthermore, we found that this
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Figure 3-10. Inhibition of tube formation by GA and Gem.
HUVEC cells were treated with GA and/or Gem for 4 h and total master segments
lengths were measured with ImageJ. a) Results of three replicates are shown as the mean
master segments length (Unit: Pixels) compared to the control. (b) Representative images
of HUVEC cell line treated and untreated(control). Magnification = 10X (scale bar =
0.5mm). Values represent the mean ± SEM from three independent experiments; **p <
0.05, ****p < 0.01.
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inhibitory effect operates via the downregulation of ribonucleotide reductase enzyme
subunit 2 (RRM2) expression, this data is also in line with the findings of Xia g et al.
(2017) they reported that GA and Gem showed a synergistic therapeutic effect on
pancreatic cancer63.
Based on results from the cell viability assay, we selected the most effective
concentration ratio of GA and Gem for NSCLC cells. The results of the MTT assay
reveled that cotreatment of GA and Gem on A549 and H1299 significantly inhibited
proliferation in a dose-dependent manner, and accordingly caused a reduction in IC50
values. This effect, validated with the Chou–Talalay method, exhibited combination
indexes that were lower than 0.9 (CI<0.9) indicating that the combination of GA and
Gem had a synergistic effect (Figure 3-3)198. Indeed, it is noteworthy to mention that the
GA concentrations used in the present study were remarkably lower than the IC50 of GA
as a single drug on both cell lines. Furthermore, we observed the similar dose-dependent
inhibitory effect on the number of colonies formed, the invasion, and migration properties
of both cell lines in the presence of the combination treatments .These studies provided
further evidence that GA+Gem were highly effective and had a synergistic anticancer
effect on NSCLC cells. Altogether, our findings on the inhibitory effect GA+Gem on cell
proliferation, colony formation, invasiveness, and migration was in accordance with the
GA inhibitory effect reported in various cancer studies 212 213 214, as well as in NSCLC215
177 176
and certainly for Gem.
The main mechanism of action for Gem is inhibiting DNA synthesis29, this
process is achieved indirectly by suppressing the ribonucleotide reductase (RR) enzyme
activity216. This enzyme converts ribonucleotide 5’-diphosphates to deoxyribonucleotide
5’-diphosphates, one of the essential steps for DNA replication168. It is also known that
the expression level of RR is inversely related to the Gem resistance 217 34. Previous
studies have shown that the expression of two subunits of the RR enzyme is related to the
sensitivity of NSCLC to Gem 36. Moreover, the RR enzyme is responsible for cell cycle
process regulation218 . Notably, our western blot results showed a significant decrease in
the expression level of RRM2 (the catalytic subunit of the RR enzyme). Furthermore,
clinical trials have shown that the poor prognosis in lung cancer correlates with high
expression levels of the subunits of RR 39 . We can suggest that this synergistical effect
cause intrinsic differences in molecular mechanism and leads to apoptosis induction and
reverse the multi drug resistance.
It is well documented that a common mechanism for chemoresistance is the
overexpression of ATP-binding cassette (ABC) efflux transporters in cancer cells such as
the P-glycoprotein efflux transporters (P-gp/ABCBl) 203. Notably, previous studies
showed the dependency of reducing P-glycoprotein transport expression (i.e., decreased
expression of the P-gp transporters) for reversing the Gem resistance in
cholangiocarcinoma 133. In addition, Gem resistance is usually reported to be a
consequence of the reduction in drug concentration within the cells due to either drug
efflux or decrease in drug influx.130 129 167 As shown, the free GA could not demonstrate
cytotoxicity with our tested concentration (highest 400μM) but when combined with
Gem shows elevated level of cytotoxicity compare to native GA and Gem. This lower

68

cytotoxicity of the Gem could be related to the MDR effect, the free drug efflux through
P-glycoprotein transporter available on the cell membrane which results to the decline in
the intracellular concentration of the drugs, our RH123 assay result (Figure 3-5). Our
results on GA sensitization on cancer cell lines via inhibition of P-gp and MDR1 are in
accordance with findings of previous investigation conducted by Wang H et al. (2015)
which showed that GA increases the accumulation of doxorubicin through reversing
MDR and suppressing P-gp efflux activity70.
Furthermore, the ability to stimulate apoptosis in different cancer cells was
proposed as one of the fundamental mechanisms for the anticancer properties of GA. Cell
cycle analysis revealed that the G2 cell population increased in response to an increase in
the dose of GA in H1299 cells. Impressively, these findings were consistent with the
previous finding that agents modulating and promoting G2 phase arrest strengthen the
cytotoxicity effect of agents that influence the DNA directly, 219 while as expected Gem
induces S phase arrest and acts on DNA (the main mechanism by which Gem causes cell
death is via apoptosis). Not surprisingly, co-treatment of Gem with GA increases the
apoptotic cell population to a greater extent than single-agent treatment.
Thus, our results suggest that combined treatment of GA and Gem inhibited the
growth and proliferation of NSCLC cells by inducing apoptosis via promoting cell cycle
arrest. This data strengthens our hypothesis, and further proves the importance of cellcycle arrest to Gem cytotoxicity. The extent of apoptosis was determined by AnnexinV/propidium iodide staining to identify and quantify the population of the cells
undergoing apoptosis. Upon exposure of cells with cotreatments of GA+Gem, an increase
in the apoptotic population was observed in A549 and H1299 cell lines, demonstrating
that GA can induce cell death via inducing apoptosis for cells treated with Gem. This
result explains the ability of GA when combined with Gem to increase the apoptotic
population.
We were able to show that elevated levels of apoptosis in cells subjected to
simultaneous treatment with both drugs was associated with downregulation of an
antiapoptotic protein, B-cell lymphoma 2 (Bcl-2), with concomitant upregulation of
pro-apoptotic proteins such as Bax, cleaved PARP and cleaved caspase-3 (known key
markers for apoptosis regulation). Similar, previous study done on GA a potent apoptotic
inducer, demonstrated downregulation of Bcl-2 and Bax expression on platinum
resistance NSCLC220.
These results provide further validation for synergetic effect of GA and Gem
when compared to Gem treatment alone as shown in previous findings.207 However,
further studies are needed to determine regulatory proteins and markers involved in
modulation of this combination of cell cycle arrest and apoptosis population at a
molecular level.
The tube formation study on endothelial HUVEC cells revealed that GA and Gem
combination showed an elevated inhibitory effect on tube formation (Figure 3-10)
similar angiogenesis inhibition effect was reported previously by Wen L et al.(2014)221.
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Hence, future investigation necessary to explore the effect of this drug combination on
the regulation of angiogenesis, and formation of blood vessels which counts as a critical
step in tumor growth. Overall our result demonstrated a superior effect of Gem treatment
on NSCLC due to GA sensitization effects.
Conclusion
This study demonstrated that GA increases the antitumor effect of Gem in
NSCLC in vitro, and that the combination of these two drugs could effectively inhibit
NSCLC growth and induce apoptosis. Moreover, our study demonstrated that GA could
suppress the expression of RRM2. Overall, these data suggest the potential effectiveness
of combination treatment with GA and Gem in patients with NSCLC. However, in order
to validate this effect, further in vivo studies followed by controlled clinical trials are
mandatory.
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CHAPTER 4. SELF-ASSEMBLED HUMAN SERUM ALBUMIN-TANNIC
ACID NANOPARTICLES FOR COMBINATION THERAPY IN NON-SMALL
CELL LUNG CANCER
Introduction
Lung cancer is a predominant cause of morbidity and mortality across the world.
Moreover, among all types of cancers, lung cancer is the leading cause of cancer
mortalities11. Non-small cell lung cancer is one of the dominant division of lung cancer
that solely represents 85-90% of all lung cancer cases 2 89. Up to the present time, primary
treatment regimens for cancer include radiation therapy, chemotherapy and surgery, with
chemotherapy being the best option thus far. Despite the eminent benefits of
chemotherapy, its value is offset by severe side effects such as renal and/or hepatic
toxicity or insufficient amounts of drug available at the target site. Such pitfalls can be
handled by employing a target-specific, biodegradable and biocompatible drug delivery
carrier. In present study, we propose a human serum albumin (HSA)-based nanoplatform
for dual loading drug delivery. Produced by the liver, HSA is the most abundant protein
in the human body, with a molecular weight of 66.5 kDa and a half-life of approximately
20 days.
The X-ray analysis shows that HSA consists of three domains (I, II and III), and
each domain has two subunits (a and b) that are considered the binding sites of the HSA
molecule121. In general, HSA is a vehicle for various substrates such as hormones, bile
acids, amino acids, metals and toxic metabolites. In recent decades, scientists have taken
advantage of this extraordinary feature by using this protein as a biodegradable and
biocompatible carrier to load therapeutic agents. HSA not only delivers drugs to their
target, but also preserves bound drugs from oxidation138. In addition, a biodegradable
carrier such as HSA can effectively influence the pharmacokinetic and pharmacodynamic
properties of anticancer agents. Furthermore, it can also modify the in vivo distribution to
be more advantageous. Due to hydrophobic pockets and hydrophilic regions in the
molecule, HSA can bind to both categories of drugs with different physical properties85.
Nanoparticles designed using an HSA basis are more favorable due to beneficial features
such as biocompatibility, biodegradability and non-immunogenicity. In addition, passive
targeting with HSA can also be considered somewhat facilitated targeting due to the
presence of the glycoprotein60 (gp60) receptor on cancer cells, which is an HSA- specific
receptor138. Abraxane® is an HSA-loaded Paclitaxel (Pxtl) nanoformulation that has
successfully been utilized to treat a number of cancers in recent years222. With this
approach, the chemotherapeutic capacity of paclitaxel—commercially available as
Taxol— reached another level, as this nanoformulation efficiently lowered the toxic
effects of Pxtl and its off-target side effects.
Nano-drug delivery systems have been employed to conquer the disadvantages of
conventional drugs. The rationale of using nanoparticles is based on their ability to
accumulate at the tumor site via the Enhanced Permeation and Retention (EPR) effect83.
Additionally, nanoparticles prolong circulation time and improve toxicity and tolerability
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issues. We selected HSA as a nanoparticle matrix because albumin is commonly used for
both lipophilic and hydrophobic drug delivery. Therefore, we developed simple,
multifunctional nanoparticles (NPs) using a human serum albumin nanoplatform base and
tannic acid as a low-toxicity stabilizer, for targeted drug delivery in the treatment of
NSCLC223-224. In our previous studies, we have shown that tannic acid has a very good
binding affinity to lung fluid, making it a suitable excipient for adding stability to our
HSA nanoparticle196. Our human serum albumin-tannic acid (HTA)-based nanoparticle is
a biocompatible nanocarrier that has a dual loading capacity for both lipophilic and
hydrophobic drug delivery.
We previously revealed that Gambogic acid (GA) and Gemcitabine (Gem)
combination therapy has a synergistic anticancer effect on NSCLC. Gem is a unique
nucleoside analog with a mild safety profile that mimics deoxycytidine and interferes
with DNA synthesis. Although Gem is water soluble agent, GA is a hydrophobic
compound. Administration of hydrophobic drugs with their organic solvents promotes in
vivo toxicity, thereby limiting clinical use. Therefore, there is an emerging interest in
encapsulating GA in nano carriers225. Utilizing HSA, hydrophobicity can become an
advantageous characteristic, as hydrophobic drugs can induce the self-assembly of HSA
proteins when mixed136. Furthermore, loading a chemotherapeutic agent, e.g. Gem, on a
nanocarrier, promotes sufficient drug delivery to the tumor environment and lowers
undesired effects226.
Using HSA as a platform for NDDS has been used widely in cancer therapy227 121.
Generally, there are three different process for the development and preparation of HSA
NPs: 1) emulsion formation, 2) solvent evaporation method), and 3) coacervation
method. The limitation of the emulation method due to adding organic solvent can be
overcome by solvent evaporation method evolved from microencapsulation by the
coacervation process228. Where particles are usually formed by drowse addition of the
acetone into the aqueous solution of HSA. This process can be further improved and lead
to the production of more stable NPs with adding a crosslinker 229 228.
Moreover, tannic acid is a hydrolysable polyphenol. This natural compound is
abundant in various plants such as fruits and tea leaves. Recently, TA gained attention as
a pharmaceutical excipient. This unique, safe molecule is not only able to increase the
water solubility of hydrophobic drugs but can also improve the stability of
self-assemblies by forming hydrophobic interactions with hydrophobic molecules230 80.
Further, TA acts as a crosslinker due to the presence of hydroxyl groups that act as
hydrogen bond donors231 201.
Therefore, in this study, we designed biodegradable and biocompatible human
serum albumin-tannic acid (HTA)-based nanoparticles loaded with a combined dosage of
GA and Gem (G-G@HTA). We further investigated the efficient internalization of these
NPs into cancer cells and determined the synergistic effect of Gem and GA on NSCLC
using in vitro and in vivo studies, with the purpose of establishing a strong and
predictable platform for use in clinical settings.
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Methods
Cancer Cell Lines and Animals
Non- small cell lung cancer cell lines, A549 (a carcinoma cell line derived from
58-year-old male Caucasian, #ATCC® CCL-185™) and H1299 (carcinoma non-small
cell LC cell line derived at the metastatic lymph node from 43-year-old adult, #ATCC®
CRL-5803™), were purchased from ATCC (American Type Cell Culture) and cultured
using Dulbecco's Modified Eagle Medium (DMEM)-F12/ Roswell Park Memorial
Institute medium (RPMI-1640, which was supplemented with 10% FBS and 1%
antibiotic/antimycotic (Gibco, Thermo Fisher Scientific, Grand Island, NY, USA)
solution at 37 °C in a humidified atmosphere (5% CO2 - 95% air atmosphere)). A new
frozen stock prepared from original stock was used every six to seven months, to
maintain the cell lines’ morphology and validity for experimentation. Animal
experiments were carried out using 6 to 8-week-old male athymic nude/nude mice
purchased from Jackson Laboratories for antitumor efficacy studies. All procedures were
in accordance with approved protocols from the University of Tennessee Health Science
Center Institutional Animal Care and Use Committee.
Chemicals, Reagents, and Antibodies
The chemicals and reagents for experimentation purposes were purchased from
Sigma Aldrich and Fisher Scientific, unless otherwise stated. Cell culture consumables
were purchased from Gibco, Thermo Fisher Scientific. Monoclonal antibodies were
purchased from Abcam or Fisher Scientific. For all cell culture studies, cell lines were
subjected to trypsin and monodispersed into appropriate plates according to the assay and
allowed to adhere overnight and reach 70-80% confluency before initialization of
treatments.
Preparation of Dual Loaded HSA Self-Assembly Nanoparticle (G-G@HTA)
The self-assembly formation was conducted using the solvent evaporation
technique232 233. Briefly, to the 500μl of human serum albumin (HSA) dissolved in an
aqueous medium (1mg/ml in Milli q filtered water),700μl of Tannic acid (1mg/ml in
Milli q filtered water) was added, formulation was in 8mL glass vial with continuous
stirring at 500 rpm on a stir plate (Benchmark stirrer, ABC Scientific, Glendale, CA,
USA) . Next, the concentration of the solution was adjusted to 1mg/ml. Then the drug
loading process occurred in two steps. Firstly, 100μL of Gem (1 mg/mL) dissolved in
water was added slowly (dropwise) to the described solution and left stirring for 30-45
min. After the solution thoroughly mixed, 100μL of GA dissolved in acetone (1 mg/mL)
was again added slowly (dropwise) to this solution and the speed increased to 900 rpm.
The resulting solution stirred overnight to evaporate the acetone, allowing the formation
of dual-loaded self-assembled nanoparticles composed of assembled HSA/TA loaded
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with GA and Gem, referred to as a GA and Gem-loaded human serum albumin-tannic
acid (G-G@HTA) self-assemblies. The solution was centrifuged at 1000 rpm for 5 min to
eliminate any unbonded and aggregated clumps. The developed G-G@HTA solution was
kept in 4˚C and used within a week. For all in vitro cell culture experiments, a freshly
made stock of G-G@HTA was used in order to protect GA and Gem activity in the
formulations.
Particle Size and Zeta Potential
The particle size of G-G@HTA nanoparticles was measured through the dynamic
light scattering (DLS) analyzer using the Zetasizer (Nano ZS, Malvern Instruments,
Malvern, UK)223. For this purpose, 20μl of developed nanoparticles was thoroughly
dispersed in 1ml of filtered Milli q water and subjected to quick probe sonication
(VirSonic Ultrasonic Cell Disrupter 100, VirTis) for 30 s in order to destroy any
aggregates formed and produce a homogeneous solution of nanoparticles234. Particle size
measurements were conducted for 3min at 25˚C, unless otherwise mentioned. The
experiments were performed in triplicates.
The average zeta potential was determined using 20μl of the described solutions
in 1× phosphate-buffered saline (PBS) solution, using the Zetasizer for 30 runs in each
reading, and data is presented as an average of three readings.
Size and Zeta Potential Stability Testing
The GA and Gem-encapsulated HTA nanoparticles were subjected to storage in
refrigerated (4 ˚C) conditions over 14 days. Every 3 days, these dual-loaded nanoparticles
were analyzed for particle size and zeta potential and were compared against 0-time point
samples.
Particle Morphology by Transmission Electron Microscope (TEM)
To analyze size and morphology, G-G@HTAs were examined by JEOL 200EX
transmission electron microscopy (TEM, JEOL Ltd, Tokyo, Japan) operating at the
voltage of 80 kV, and the grids were prepared by placing a drop of a probe sonicated (30
sec) G-G@HTA solution on the shiny side of 150 mesh TEM grid (Electron Microscopy
Sciences, PA, USA), followed by a two time phosphate-buffered saline (PBS) wash, and
left for drying235 85. Afterward, grids were stained using a 2% (w/v) uranyl acetate
solution. Different regions of these grids were imaged with the above mentioned TEM
system using an AMT camera203 230 (Magnification =100 000X).
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Fourier Transform Infrared Spectroscopy (FTIR) Analysis
Formation of G-G@HTA nanoparticles was confirmed by FTIR analysis. The
actual lyophilized samples of G-G@HTA with their respective individual compositions
(TA, HSA, GA and Gem) were prepared and placed on ATR sampling Accessory plate
and recorded using the Spectrum 100 FTIR spectrophotometer (Perkin Elmer, Waltham,
MA) instrument. Relevant spectra were obtained between 4000 and 650 cm−180 236 230.
Fluorescence Quenching
For further validation of G-G@HTA nanoparticle formation, the fluorescence
binding assay was performed on the SpectraMax Plus plate reader (Molecular Devices,
Sunnyvale, CA, USA). In order to achieve that objective, the spectra were documented in
the wavelength range of 250  400nm upon excitation at 295nm, using 5nm/2nm slit
widths, and each spectrum was the average of three scans236,237 . The stock solution of
100 mg of HSA solution in 1ml of PBS was titrated via successive addition of the stock
solution of TA (1mg/ml Water) in a quartz cuvette, to give final concentrations in the
range 0  100μg TA in the whole solution196.
Cellular Uptake Assay
Cumarin6 (C6)-loaded G-G@HTA NPs were developed following the previously
described procedure80 196 to assess the HTA NPs delivery capability. To investigate the
enhanced uptake of drugs in NSCLC cells, A549 and H1299 cells (0.5×106 cells/well)
were cultured in a six-well plate in their respective fresh media, left for overnight
adhesion to the plate surfaces, and incubated in a CO2 incubator at 37 °C. The next day,
the cells were treated with 2.5, 5 and 10μg of C6-labeled G-G@HTA, for 3 h for the dose
dependency study. Cells were treated with 5μg of C6-labeled G-G@HTA for 1,3 and 6 h
for the time dependency study 203 238. The cells were washed thrice with PBS to wash out
any superficially bound formulation or dye. After their respective incubation duration, the
media was changed to fresh phenol red-free media, and cells were analyzed for
internalization using the NovoCyte FACS machine (ACEA NovoCyte 1000, ACEA
Biosciences, Inc. San Diego, Ca, USA) in a FITC channel (fluorescence measurements at
λex: 485nm and λem: 520nm). The mean fluorescence intensity (MFI) was documented
from three independent measurements. For visualization support, cells were subjected to
EVOS 214 FL Imaging System in a GFP channel (AMF4300, Life Technologies,
Carlsbad, CA, USA)203 239.
Cell Viability Assay
A549 and H1299 Cells were seeded into 96-well plates at 0.5×104 cells/well, 48h
after the indicated treatments ((0.01-0.2nM of GA, 0.01-0.2nM of Gem, and equivalent
concentration of Ga+ Gem, G-G@HTA, and HTA NP), and cell viability was
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determined using the MTT reagent (Promega, Madison, WI, USA). Absorbance was
measured at 570nm after 2-4 h incubation with the MTT reagent, using a Microplate
Reader (BioTeK Cytation 3, Winooski, VT, USA)195. Each treatment concentration was
studied in triplicate. Viability of the treated cells was examined with respect to the
untreated cells (control). In addition, the cell morphology upon incubation with treatment
and without treatment was imaged using EVOS® FL Imaging System at 20X
magnification176 179.
Colony Formation Assay
Using 12-well plates, approximately 300-400 cells were seeded per well. After
overnight incubation to allow cells to adhere to plate surfaces, cells were subjected to
incubation with the indicated treatments (25nM Ga+25nM Gem and equivalent
concentration of G-G@HTA and HTA NP). After 14 days of culture, cells were washed
with PBS, fixed with cold methanol and stained with 0.5% crystal violet. Representative
images from each well were used for counting the number of colonies formed, and the
mean of three independent treated wells was reported236.
Migration Assay
To examine the ability of the treated cells to migrate, A549 and H1299 cells were
seeded into the upper chamber of a 24-well transwell insert (8-μm pores, BD Biosciences,
San Jose, CA) after 24h starvation in FBS free media. 5×104 cells were seeded per well,
with FBS free medium plus the indicated treatments (50nM Ga+50nM Gem and
equivalent concentration of G-G@HTA and HTA NP)76. The respective complete
medium was added into the lower chamber and incubated for 18 h. After end of the time
point, any cells that migrated through the pores from the bottom of the upper chamber’s
membrane to the lower surface of the chamber, were fixed with cold 4%
paraformaldehyde for 30 min and stained with 0.1% crystal violet. The remaining cells
on the surface of the upper chamber were gently wiped off with a cotton swab. Three
randomly selected regions on each well were imaged using a Keyence microscope BZX800(Itasca, IL, USA), and the number of cells in each field was counted with help of
ImageJ software240.
Invasion Assay
To test the NSCLC cells’ ability to invade, cells were subjected to 24h starvation,
and an invasion assay was performed using BioCoat Matrigel Invasion Chambers (BD
Biosciences, Bedford, MA, USA). The upper chambers of the trans-well plate were
pre-coated with Matrigel and seeded with 3.5×104 A549 and H1299 cells per well, using
serum-free media. The same media was placed in the lower chambers. After 24h
incubation to allow cells to adhere to the plate surface, the media was replaced with fresh
FBS-free media, containing the indicated treatment concentration. Cells without
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treatment served as the control group. After 24h, any NSCLC cells that invaded the lower
chamber were fixed with cold 4% paraformaldehyde, stained with crystal violet and
subjected to imaging with the Keyence microscope241 201. This experiment was repeated
three times, and quantification was performed using ImageJ software.
Xenograft Tumor Model
Six-week-old male athymic nude (nu/nu) mice, purchased from Jackson
laboratory, were housed and maintained in a pathogen-free environment for two weeks
before the study began. Each mouse was injected subcutaneously into the right flank with
1×107 A549 cells suspended in 100μl PBS, containing 1% (v/v) Matrigel. Once the
average tumor volume reached 100mm3, mice were randomly divided into four treatment
groups, including a PBS only control group (n=4): nanoparticle control (HTA only), GA
(2 mg kg-1), Gem (20 mg kg-1) and a combination equivalent (GA +Gem). Respective
dual-loaded nanoparticles (G+G@HTA) were administered biweekly via the
intraperitoneal route, for four subsequent weeks. Mouse weights and tumor growth rates
were monitored twice, and overall health was simultaneously observed closely. Tumor
volume (V) was estimated by measuring the length (L), width (W), and height (H) of the
tumor, using this formula: V =0.5236 (L x W x H). Four weeks after the first drug
injection, mice were euthanized, and tumor burden (wet weight) and metastases were
measured. Pictures were taken for visual representation, and organs, blood and tumors
were excised and stored at -80 ˚C until further analysis242 175. For this study, animal care
and handling were performed in accordance with institutional guidelines, and all animal
experiments were done using protocols approved by the Institutional Animal Care and
Use Committee (IACUC).
Blood Analysis
At the end of the treatment, mice were sacrificed with CO2 exposure and cervical
dislocation. Blood samples were collected (cardiac stick post-euthanasia) from each
mouse, and serum samples were isolated for further clinical chemistry. To test Kidney
and hepatic function in treated groups compared to the control (no treatment) group,
Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline
phosphatase (ALP), Total protein (TP), Total bilirubin (TBili), Albumin (Alb), Creatinine
(create), Blood urea nitrogen (BUN), Glucose (Glu) were measured from serum samples
utilizing a DiaSys Response 910 Vet Chemistry Analyzer (DiaSys Diagnostic Systems,
USA, LLC, Wixom, MI)243 231.
Immunohistochemistry and Histopathologic Examination
Immunohistochemical studies (IHC) of tumor tissue slides were investigated by
probing with apoptotic, antiapoptotic and regulatory proteins and their respective
antibodies. Immunohistochemical analyses were conducted following a previously
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developed protocol in our lab205. Briefly, slides were dewaxed at 65 °C for 30 min
followed by two 10 min washes with xylene and then rehydrated with different
concentrations of ethanol, including 100%, 90%, 70%, 60%, 50%, in sequence and
finally with distilled water for 5 min each. Next, the slides were put into triton x-100 and
were kept for 5 min. Then, the endogenous peroxidase activity was inhibited by hydrogen
peroxide for 5min, following incubation with antigen retrieval to unmasked epitopes for
45min. After blocking with background sniper (BioCare Medical, CA, USA) for 30 min,
the slides were incubated with Bcl2 (1:1200 dilution), Bak (1:400 dilution), MDR1
(1:800 dilution), and RRM2(1:100 dilution) overnight at 4 °C. The sections were then
incubated for 1 h with a respective secondary antibody. After hematoxylin counterstain
and dehydration, the sections were sealed with cover slips. The images were taken by
using Keyence microscope. In addition, the major organs (heart, liver, spleen, lung, and
kidney) which were harvested at the end of the study were kept in 10% neutral formalin.
Formalin-fixed tissues were sectioned and further stained with H& E and observed under
an optical microscope244 245.
In Vivo and ex Vivo Tumor Targeting HTA NP Imaging
To conduct an investigation on biodistribution and the tumor targeting ability of
HTAs, in vivo imaging was employed on mice bearing an A549 xenograft tumor. For the
purpose of this study, mice were on special Teklad Global Rodent Diets (Envigo,
Huntingdon, United Kingdom) to prevent and halt any possible background fluorescence
as a consequence of a normal diet. Once the tumor volume reached ~300-500mm3, mice
were randomly segregated to two individual groups (3 mice/group). A one-time the
intraperitoneal (IP) injection of free-Indocyanine green (ICG) dye (100μg/mice in 100μL
PBS) was used for the control group. The second group was injected with ICG-tagged
HTA (100μg ICG-equivalent HTAs/mice in 100μL PBS,) via IP route. For preparation,
the same encapsulating method of the C6-HTA was followed according to previously
developed, where C6 was substituted with ICG. Briefly, 100μl of freshly made HTA
stock solution and ICG solution (1 mg/ml in water) were thoroughly mixed and incubated
at room temperature, while stirring for 20 min. In each mouse, distribution and tumor
accumulation of ICG dye and ICG-tagged HTA were monitored at different time points
(3, 6, 24, 48, and 72h) using an IVIS XRMS Imaging System (Caliper Life Sciences,
Waltham, MA) armed with a coupled device camera (CCD) at Ex: 785nm, Em: 820nm.
After 72h, mice were sacrificed. Tumors and major organs, e.g. heart, lung, liver, kidney,
and spleen, were collected for ex vivo imaging246 247.
Statistical Analysis
All acquired data were analyzed via Graph pad Prism 5.03 Software (GraphPad
Software, San Diego, CA), and results were displayed as a mean of three individual
readings ± standard error of mean (SEM). All statistical analysis was performed using
student’s t test. A p value ≤ 0.05 was considered statistically significant.
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Results
Size and Morphology Characterization
The common solvent evaporation method was followed for the preparation of
HTA self-assemblies demonstrating reproducible and scalable results. Tannic acid was
added to the self-assemblies as a stabilizer due to TA’s ability to form hydrogen bonds
and/or crosslink with HSA, which occurs due to noncovalent interactions (π–π stacking),
making a firm and secure network in the solution. Moreover, the presence of TA
promotes a stable matrix that allows GA and Gem molecules to be encapsulated
efficiently.
As measured by DLS in water, the average particle size of G-G@HTA NPs was
205.4±7.6nm, the average zeta potential was -22±3.12 mV, and the polydispersity index
was 0.22±0.009 (Figure 4-1a). Measurements illustrate that the developed nanoparticles
were evenly dispersed, with minor size alterations. The G-G@HTA NPs average size is
in the approved size range of nanoparticles for preclinical and clinical studies of cancer
therapy78. Furthermore, it is well-documented that nanoparticles with zeta potential
(surface charge) values between +30 mV to -30mV typically have high degrees of
stability248. It is noteworthy that a negative charge is favorable for greater cellular uptake
and lower systemic toxicity76 135(Figure 4-1b).
Transmission electron microscopy (TEM) images provided additional evidence
that the G-G@HTA nanoparticles have a uniform, spherical shape and confirm their
average size of ⁓ 185nm (Figure 4-1d)). This size reduction is excepted, as the
dehydrated form of the nanoparticle has a smaller size versus the hydrated form measured
by the DLS machine.
Moreover, based on our stability test over 14 days, the size and zeta potential had
a narrow variation range (164.167±21.1 to 209.667±30.74nm and -18.9±0.77 to -21.77
±0.98 mV), demonstrating a stable size (Figure 4-1e) and zeta potential of G-G@HTA
NPs over time, (Figure 4-1f)206.
Fourier Transform Infrared Spectroscopy (FTIR)
To confirm the presence of each individual component of G-G@HTA NPs (HSA,
TA, GA and Gem), the molecular composition was examined by FTIR spectroscopy with
demonstrating the characteristic peaks of TA, GA, Gem, HSA( Figure 4-2a). Peaks at
~1700 c cm−1, ~1603 cm−1, and ~1198 cm−1 are associated with the characteristic peaks of
CO stretching, aromatic CC stretching, and phenolic CO stretching, respectively, that are
present in TA. Spectroscopy shows that these characteristic peaks are also present in
HTA NPs and the G-G loaded HTA NPs. Furthermore, characteristic vibrational peaks of
Gem include ~2920, ~2850 cm−1 (CH2 stretching) ~1689 cm−1 (C=O stretching) and
~1053 cm−1 (C-O stretching).in addition the characteristic peak of GA (=-C-H stretching)
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Figure 4-1. Characterization studies of G-G@HTA NPs.
(a)Schematic representation of G-G@HTA NPs preparation. (b) Size distribution, (c)
Zeta potential, (d) Transmission electron microscopy TE. (e-f) Stability testing over time.
(e) Size distribution and (f) zeta potential., (g) Fourier transform infrared spectroscopy
(FTIR), (h) Fluorescence quenching. MFI=Mean fluorescence intensity.
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Figure 4-2. Spectral and biological confirmation of G-G@HTA NPs formation.
(a) Fourier transform infrared spectroscopy (FTIR) demonstrate the characteristic peaks
of excipients, representing the presence of all molecules in final formulation. (b) and
fluorescence quenching of HSA and TA exhibits the instant binding of TA to HSA as
measured by reduction of fluorescence intensity. MFI=Mean fluorescence intensity.
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appears to be around 3280 Regarding HSA, alterations in the secondary structure of its
two main amides were investigated by observing amide I and amide II bands. Amide I
showed a characteristic peak at ~1652 cm-1 (N-H stretching) in native HSA that shifted
slightly to ~1646 cm-1 in HTA and to ~ 1643 cm-1 in G-G@HTA, which is assigned to
the absorption of an α-helix peak. Similarly, the amide II band moved to ~1534cm-1 in
HTA and to ~1537cm-1 in G-G@HTA, compared to ~1527cm-1 in native HSA. Amide I
band intensity corresponds to α-helix related C = O vibrational stretching, while amide II
corresponds to N-H and C-N stretching. While other peaks in HTA and G-G@HTA
coincide with characteristic peaks of GA, Gem and TA. This is a clear indication of
successful development of HTA NPs and loading of Gem and GA on G-G@HTA
nanoparticles.
Binding Affinity of Tannic Acid to Human Serum Albumin
A fluorescence quenching assay was employed to study the affinity of TA to
HSA, two components of the HTA NPs. The degree of binding affinity was determined
by the ability of TA to reduce HSA’s tryptophan (Trp) residues196. A significant decrease
in Trp fluorescence intensity was observed after additive titration of TA to HSA solution
in PBS, indicating that the Trp residues were buried within TA layers upon binding of TA
to the HSA molecule, leaving fewer uncovered Trp residues (Figure 4-2b). This finding
is in agreement with our pervious finding in chapter one, where TA showed excellent
binding affinity to lung fluid, which contains a large amount of HSA. The observed
binding affinity is associated with hydrogen bonding and electrostatic interactions
occurring between HSA and TA.
Cellular Uptake of HTA NPs by NSCLC
The quantitative and qualitative assessment of HTA NP uptake by NSCLC cells
was performed by treating the cells with green fluorescent dye (Coumarin-6)-tagged
HTA NPs containing Coumarin-6. The cellular uptake of HTA NPs was examined in
A549 and H1299 cells by flow cytometry analysis. Following an increase in
concentration of NPs, a cell population gradually shifted towards higher fluorescence,
showing a concentration-dependent increase in the cellular uptake of NPs compared to
the unstained control cells (Figure 4-3). Similar results were observed after increasing
the incubation time with a fixed concentration of the coumarin-6-HTA NPs, as the
fluorescence intensity significantly increased with a higher incubation time (Figure 4-4).
For instance, in A549 cell lines, the cells treated with 2.5 and 5 μg /mL NPs had a mean
fluorescence intensity of (9.2×105 and 15.5×105), respectively, whereas cells treated with
10 μg/ mL NPs had the highest mean fluorescence intensity (37×105), associated with
higher cellular uptake. When treated with 5 μg /mL NPs for 1 and 3 h, cells had a mean
fluorescence intensity of (8.9×105 and 15.6×105), respectively, whereas cells treated for 6
h had the highest mean fluorescence intensity (37.7×105), illustrating a higher cellular
uptake. Moreover, successful internalization of the coumarin-6-HTA NPs (green
fluorescent-tagged NPs) in cells was further evidenced by the representative
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Figure 4-3. Dose dependency intracellular uptake of HTA NPs NSCLC.
(Cellular uptake of HTA nanoparticles tagged fluorescence dye (Coumarin 6) in A549
and H1299 cell lines in a dose dependent manner (2.5, 5, 10μg) after 3 h incubation, (a)
Graphical representation of quantitative analysis, (b). Representative fluorescence
microscopic images of cellular uptake of fluorescently labeled were imaged under EVOS
214 FL Imaging System in a GFP channel. All statistical analysis was performed using a
student’s t test. Bars represent mean ± SEM. The significance level was * p < 0.05. MFI
=Mean fluorescence intensity.
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Figure 4-4. Time dependency intracellular uptake of HTA NPs NSCLC.
(Cellular uptake of HTA nanoparticles tagged fluorescence dye (Coumarin 6) in A549
and H1299 cell lines in a time dependent manner (1,3,6h) incubated with 5μg of HTA
NPS (a) Graphical representation of quantitative analysis, (b). Representative
fluorescence microscopic images of cellular uptake of fluorescently labeled were imaged
under EVOS 214 FL Imaging System in a GFP channel (Magnification 20X). All
statistical analysis was performed using a student’s t test. Bars represent mean ± SEM.
The significance level was * p < 0.05. MFI =Mean fluorescence intensity.
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fluorescent images of the cells in dose (Figure 4-3) and time (Figure 4-4) dependency
manner. In control cells, no fluorescence was observed, whereas cells treated with
different concentrations of coumarin-6-loaded NPs demonstrated a concentrationdependent enhancement in mean fluorescence intensity, corresponding to an increased
concentration of internalized HTA NPs.
Superior Inhibition Effect of G-G@HTA on NSCLC Cells Proliferation
The effect of G-G@HTA NPs on the viability of A549 and H1299 NSCLC cells
was quantitatively studied by MTT assay and qualitatively by taking representative
images. The assay revealed that the viability of the cells decreased gradually with
increasing concentration of G-G@HTA as compared to control cells, single drugs and
combination treatment, as shown in Figure 4-5, which may be correlated with the
successful and sufficient delivery of GA and Gem into NSCLC cells. For example, at
0.1nM GA and 0.1nM of Gem and the equivalent combination concentration treatments,
the percent proliferation remained at 89%, 49%, and 30%, respectively, in A549 cells.
The percent proliferation of G-G@HTAs at the same concentration was prominently
reduced to 17%, respectively, suggesting that cytotoxicity is highly influenced by the
implementation of nano-carriers. Treatment with G-G@HTA NPs clearly and
systematically resulted in dose-dependent cell death, indicating the development of a
suitable drug delivery system. Moreover, bare HTA NPs were also examined for their
ability to induce cytotoxicity in NSCLC. The bare HTA NPs were found to be non-toxic
(cell viability > 95%) as shown in Figure 4-5, confirming the biocompatibility of the
bare nanocarrier. However, when loaded with GA and Gem, NP treatment resulted in
significantly higher (p<0.001) cytotoxicity than that of free GA or Gem alone and
cotreatment with the free drugs. Greater cytotoxicity is primarily attributed to the
enhanced nanoparticle-mediated internalization of drugs (GA and Gem) via endocytosis
pathways, as well as improved water solubility and stability of GA, which could protect
the drug from hydrolysis and fast clearance, thereby leading to the enhancement of
therapeutic function. Hence, based on a significant reduction in the percentage of cell
viability, it can be suggested that the therapeutic potential of G-G@HTA NPs is not due
to the carrier, but due to the encapsulated anticancer agents.
Treatment with G-G@HTA Reduces NSCLC Cells Colony Formation Ability in
Vitro
To investigate the inhibitory effect of GA and Gem co-treatment compared to
HTA NPs loaded with GA and Gem (G-G@HTA) on colony formation ability of NSCLC
metastasis, colony formation assay was investigated on A549 and H1299 cell lines.
In these experiments, NSCLC cell lines were treated with 50nM of GA and 50nM
of Gem, in addition to equivalent drug concentrations loaded into HTA NPs (GG@HTA), (Figure 4-6). Our results indicate that G-G@HTA significantly reduces the
ability of NSCLC cells to form colonies and reduce them by 76% and 84% in A549 and
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Figure 4-5. Anti-proliferative efficacy of G-G@HTA NPs in NSCLC cancer cells.
Cell proliferation measured by MTT assay. (a) G-G@HTA NPs inhibited proliferation of
non-small cell lung cancer (A549 and H1299) after treatment with 25-200nM Gem and
GA or equivalent amount of drugs for G-G and G-G@HTA NPs for 48h. Untreated cells
were used as control, as well as HTA NPs as a vehicle control. (b) Representative images
for highest dosage taken after 48h.
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Figure 4-6. Anti-clonogenic potency of G-G@HTA NPs.
(a) Representative images of the effect of Gem and GA, co-treatment(G-G) and GG@HTA NPs (equivalent to 25nM of Gem and 25nM of GA) on A549 and H1299 cells
after 15 days for the colony forming ability on NSCLC. b) Quantities analysis: number of
colonies formed in presence of each treatment groups; untreated cells (control) were
considered as 100 % clonogenicity. HTA NPS used as a vehicle control. All statistical
analysis was performed using a student’s t test. Bars represent mean ± SEM. * and **
represent the level of significance with P (<0.05, 0.01) with respect to control.
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H1299, respectively, relative to the untreated group. Collectively, as expected,
G-G@HTA could significantly inhibit the colony formation ability of A549 and H1299
cell lines in vitro.
G-G@HTA Can Significantly Suppress NSCLC Cells Invasion and Migration
To investigate the inhibitory effect of co-treatment with GA and Gem compared
to HTA NPs loaded with GA and Gem (G-G@HTA) in NSCLC metastasis, cell
migration and invasion were investigated by Boyden chamber and transwell invasion
assays, respectively.
In these experiments, NSCLC cell lines (A549 and H1299) were treated with
50nM of GA and 50nM of Gem, in addition to equivalent drug concentrations loaded into
HTA NPs (G-G@HTA). Our results indicate that G-G@HTA significantly reduces the
ability of NSCLC cells to invade neighboring cells by 88% and 94% in A549 and H1299,
respectively, relative to the untreated group (Figure 4-7).
Furthermore, similar results were observed in respect to cell migration ability, as
shown in Figure 4-8 G-G@HTA significantly reduces the ability of NSCLC cells to
migrate to neighboring cells by 86 and 92% in A549 and H1299, respectively, relative to
the untreated group. Collectively, as expected, G-G@HTA could significantly inhibit the
migration and invasion ability of A549 and H1299 cell lines in vitro.
G-G@HTA NPs Induce Regression of A549 Tumor Xenografts
A xenograft in vivo model was designed to confirm the synergistic effect of GA
and Gem as achieved in in vitro studies. These compounds were tested against tumor
growth on a subcutaneous xenograft model using A549 cells to develop a tumor in
(nu/nu) mice. Our data demonstrate that GA combined with Gem showed a greater
reduction in tumor growth compared to single agents (Figure 4-9a). In the same pattern,
tumor volumes in the treatment group showed greater reduction than in the control group
(Figure 4-9b); however, the degree of inhibition in the different groups varied. In the GA
single agent group, as expected, tumor growth inhibition was not significant, while GA in
combination with Gem yielded significantly smaller tumor volumes than Gem used
alone. At 36 days, the mean tumor volume in the control group was 1002 ± 75mm3.
Further, the bare HTA-treated group (a vehicle control) had no significant difference
compared to the untreated group (989± 70mm3), illustrating that tumor regression was
unrelated to the HTA vehicle. In comparison to the control group, the tumor inhibition
rates were 85 %, 49 %, 29 %, and 19 % in the GA, GEM, combination and G-G@HTA
groups, respectively. Graphed tumor weight measurements (Figure 4-9b) and net tumor
growth (Figure 4-9c) were also persistent with those of tumor size. These results
demonstrate that GA and Gem combination therapy could act synergistically against
NSCLC tumors in an in vivo model, and among all groups, tumor regression and growth
inhibition was significantly enhanced with G-G@HTA NPs.
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Figure 4-7. Anti-metastatic potential of G-G@HTA NPs measured by migration
assays.
Migration assay to determine inhibition potential of NSCLC cell lines (A549 and H1299)
after exposure to co treatment of 50nM of GA and 50nM of Gem or G-G@HTA NPs
(GA and Gem equivalent) for 24h. (a) Representative images, taken by a Keyence
microscope BZ-X800(Itasca, IL, USA) imaging System. (b) Quantitative graphical
representation. Data represented as mean ±SEM of the mean (n = 3). Bars represent mean
± SEM. * and **represent the level of significance with P (<0.05, 0.01) with respect to
control.
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Figure 4-8. Anti-metastatic potential of G-G@HTA NPs measured by invasion
assays.
Matrigel Invasion assay demonstrating similar effects, upon treatment with G-G@HTA
NPs and GA+Gem (co-treatment of 50nM GA +50nM Gem and G-G@HTA equivalent
to GA+Gem concentration)for 24h. (c) Representative images, taken by a Keyence
microscope, (d) respective Quantitative graphical representation. Bar graphs represents
the number of invaded cells with each treatment group, untreated cells served as control
and was considered as 100% and other treatment groups expressed as percentage with
respect to the invaded control cells, and HTA NPs treated group served as a NP vehicle.
Data represented as mean ±SEM of the mean (n = 3). Bars represent mean ± SEM. * and
**represent the level of significance with P (<0.05, 0.01) with respect to control.
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Figure 4-9. Anti-tumor activity of G-G@HTAs in mice bearing A549 xenograft
tumors.
Effect of GA, Gem, GA+Gem(G-G) and G-G@HTA NPs on A549 derived xenograft
tumors in athymic nude mice, untreated group representing control and HTA treated
group present NP vehicle group. Mice were randomly divided into four treatment groups,
including a PBS only control group: nanoparticle control (HTA only), GA (2 mg kg-1),
Gem (20 mg kg-1) and a combination equivalent (GA +Gem). Respective dual-loaded
nanoparticles (G+G@HTA) were administered biweekly via the intraperitoneal route, for
four subsequent weeks: (a) Tumor volume(mm3); (b) tumor weights(g); (c) Net tumor
growth(mm3), (d) Excised tumor images from treated mice; (e) Immunohistochemistry
studies (IHC) of GA, Gem and GA+Gem(G-G) and G-G@HTA NPs treated A549
NSCLC xenografts. Paraffin-embedded sections of A549 bearing tumors in nude mice
were processed and IHC was done. IHC of Bcl2, MDR1, BAK, and RRM2,
representative of three independent experiments. Data presented as mean ± SEM, each
performed in triplicate. All statistical analysis was performed using student’s t test. Bars
represent mean ± SEM. *, ** and *** represent the level of significance with P (<0.05,
0.01, and 0.005) with respect to control.
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Chemistry panels showing markers such as alanine transaminase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase test (ALP), gamma-glutamyl
transpeptidase (GGT), glutamate dehydrogenase (GLDH), blood urea nitrogen (BUN),
albumin (ALB), total bilirubin (Tbili), creatinine (Create), and glucose (Glu), which
measures liver and kidney function, were in the acceptable range and did not show any
significant abnormalities. Chemistry panel values for the G-G@HTA NP group were
within reference range values, which further demonstrated supportive data for the safety
of G-G@HTA NPs ( Table 4-1).
Taken together, our results illustrate that G-G@HTA NPs treatment could
efficaciously, safely, and synergistically restrict tumor growth in NSCLC cancer mouse
model.
G-G@HTA Promoted Apoptosis and Restrained Tumor Proliferation in Vivo
To elucidate the mechanism of G-G@HTA on in vivo tumor growth, tissue
sections from each group were collected and assayed for various biomarkers. Figure
4-10, demonstrates the significant upregulation of the apoptotic marker, Bak, and
downregulation of survival markers, Bcl-2 and MDR1, in the G-G@HTA treatment
group compared to the control group, single agent groups and the combination group.
Moreover, RRM2, a biomarker associated with Gem resistance, was significantly
downregulated in the G-G@HTA treatment group.
Furthermore, the H&E staining images(Figure 4-11) revealed no obvious damage
to major organs in the G-G@HTA group, which suggests a lack of systemic toxicity
following treatment. Likewise, the image shown in Figure 4-12 provides evidence of the
hemocompatibility of our formulation with red blood cell (RBC) membranes in mice.
These pictures show comparable results for RBC morphologies among HTA,
G-G@HTA, and control groups. Taken together, these results indicate that the
administration of G-G@HTA two times per week, for four continuous weeks, can be
considered safe.
In Vivo Biodistribution of HTA NPs
To Examine and evaluate the in vivo biodistribution and tumor targeting ability of
the HTA NPs, the IVIS XRMS was employed to visualize and quantify the amount of
HTA NPs that accumulated in nude mice bearing A549 tumors. ICG that fluoresces at the
near infra-red (NIR) region was encapsulated within HTA NPs. Due to unspecific
distribution, free ICG mice showed fluorescence that circulated throughout the body at
initial hours a, gradually diminishing after 6 h. However, the fluorescence in groups
injected with ICG-tagged HTA NPs was slowly detected throughout the mouse body. We
speculate that these findings are due to a prolonged circulation time and slow distribution,
known advantages when using NPs. A strong fluorescence intensity (FI) was observed in
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Table 4-1.

Parameters

Chemistry panel analysis of the plasma serum of mice after treatments: hepatic and kidney function enzymes.
References
Normal
Units
range

Control

HTA NPs

Treatment groups
GA
Gem

G-G

G-G @HTA

Alb

2.5-3.5

g/dL

2.7±0.2

3.4±1.3

3.42±1.2

2.53±0.3

3.05±0.01

3±0.03

ALP

35-96

U/L

30±0.32

56±3.2

43±23.1

21±1.2

50±17.1

38±12.3

ALT

17-77

U/L

39±1.2

45.34±13.5

61.5±11.3

26.25±5.2

168±1.3

45±10.3

AST

54-298

U/L

226±0.2

188.34±65

174.5±65.3

86.25±21.3

145±56.3

246±35.5

BUN

8-33

mg/dL

16.67±0.9

18.5±3.2

18.5±4.2

20.5±1.3

22±6.01

15.5±0.3

Creat

0.2-0.9

mg/dL

0.67±2.72

0.33±0.1

0.425±0.1

0.67±0.1

0.625±0.3

0.47±0.03

Glu

62-175

mg/dL

131.67±0.9

168.3±45.3

214±13.2

224.75±28.32

317±41.3

136.5±29.3

TBili

0.0-0.9

mg/dL

0.125±0.3

0.13±0.02

0.125±0.1

0.125±0.1

0.15±0.1

0.125±0.006

TP

3.5-7.2

g/dL

4.87±0.5

5.64±0.9

6.65±3.2

5.5±0.3

6.6±0.1

5.6±2.2

Note: ALT= alanine transaminase, AST=aspartate aminotransferase, ALP= alkaline phosphatase test, GGT= gamma-glutamyl
transpeptidase, GLDH= glutamate dehydrogenase, BUN= blood urea nitrogen, ALB= albumin, Tbili= total bilirubin, Create=
creatinine, and Glu= glucose.
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Figure 4-10. Immunohistochemistry and histopathologic examination.
Immunohistochemistry studies (IHC) of GA, Gem and GA+Gem(G-G) and G-G@HTA
NPs treated A549 NSCLC xenografts. Paraffin-embedded sections of A549 bearing
tumors in nude mice were processed and IHC was done. IHC of Bcl2, MDR1, BAK, and
RRM2, representative of three independent experiments.
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Figure 4-11. Biocompatible and toxicity studies of G-G@HTA NPs.
H&E staining of major organs (heart, spleen, lung, liver, and kidney) and tumors of mice
treated with HTA vehicle, GA, Gem, both drugs in combination and G-G@HTA NPs.

Figure 4-12. Hemocompatibility studies of G-G@HTA NPs.
Representative images of RBC morphology of mice blood treated with HTA vehicle, GA,
Gem, both drugs in combination and G-G@HTA NPs.
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tumor areas for all in the ICG-tagged HTA group after 6 h, which is imputed to the
targeted accumulation of ICG-tagged HTA in tumor tissue via the enhanced permeability
and retention effect. Moreover, FI signals on tumor sites increased from the 24h
timepoint, whereas FI signals observed in the ICG group were slowly eliminated. The FI
signal of the HTA group remained strong throughout the imaging study (72h). Hence, it
can be proposed that HTA NPs assist and mediate the delivery of therapeutics into the
tumor tissue with an extended retention period, which would improve and strengthen the
antitumor efficacy. On another note, free ICG exhibited no accumulation at the tumor site
during the imaging period, due to fast clearance and rapid diffusion after IP
administration (Figure 4-13). For further evidence and a clear FI signal observation, the
tumors and major organs (Heart, liver, kidney, lung and spleen) were collected at 72h
post-injection. The Ex Vivo images of dissected organs and tumors are displayed
in Figure 4-13b. As shown in the figures, zero FI signals were detected in tumors from
the ICG group, while powerful FI signals are evident in tumor tissues from mice in the
ICG-tagged HTA group. No significant fluorescent uptake was observed in the hearts,
lungs, spleens, and kidneys. However, the FI signal from ICG-tagged HTAs was slightly
detected in liver and lung tissue from all groups Figure 4-13c.
Discussion
Gem is an antimetabolite anticancer agent with an excellent record in clinical
studies for various cancer types, including NSCLC. However, due to increasing drug
resistance, its therapeutic efficacy has been compromised. At the same time, GA is a
natural anticancer agent, potent apoptosis inducer, and chemo-sensitizer, making it an
ideal candidate for combination with Gem.
The foundation of this study is built on the basis of our previous findings (Chapter
3), where we described a combinatorial dosage of GA and Gem and demonstrated their
synergistic effect on NSCLC; GA sensitizes NSCLC to Gem therapy.
In order to overcome the water insolubility issue of GA and further reduce the
development of Gem resistance, as well as avoid off-target side effects, we sought to
design a human serum albumin-tannic acid nanoparticle and encapsulate GA and Gem
for specific delivery to NSCLC (G-G@HTA NPs).
We have successfully developed and characterized HTA nanocarriers with dual
loading properties for both hydrophobic and hydrophilic drugs; his drug delivery system
(DDS) has several advantages features. Firstly, it is composed from safe excipients that
are biodegradable and biocompatible. A cross-linked HSA with TA gives a stable
platform that does not raise any immunogenicity issues. Secondly this carrier can
simultaneously deliver both Gem and GA as its chemo-sensitizer. This cargo has
relatively lower toxicity than other common combination therapies for NSCLC as GA is
known to have a safe toxicity profile65. Thus, this nano carrier assist to overcome the
resistance issue, deliver adequate quantities of drugs specifically to the tumor site via the
EPR effect and internalizing them within the cancer cells through 60kDa glycoprotein
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Figure 4-13. Tumor targeting ability of HTA NPs.
(a) In vivo fluorescent imaging of mice bearing A549 xenograft tumors treated with free
dye (Indocyanine green (ICG)) and dye loaded nanoparticles (ICG-HTA NPs). The mice
treated with dye and ICG labeled HTA NPs were imaged using the IVIS Lumina XRMS
in vivo imaging system at various time intervals (3, 6, 24, 48, and 72h). (b) Ex vivo
imaging of tumors and major organs (kidney(K), liver (Li), lung(Lu), heart, spleen(S) and
tumor(T)) captured from euthanized mice treated with dye and ICG-HTA NPs after 72h.
(c)Quantitative ex vivo analysis of the fluorescence signals of tumor and major organs,
All statistical analysis was performed using a student’s t test. Data is presented as mean ±
standard error of the mean n = 3 for in vivo and ex vivo imaging. *** represent the level
of significance with P (<0.001) with respect to control.
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(gp60) and caveolin-1-mediated transcytosis receptors. Finally, this nanocarrier would
prolong the circulation time of the drugs, increase their water solubility, lower incidence
of side effects, decrease the required dosage of the drugs, and reduce the development
resistance.79
HSA is an excellent platform for drug delivery as it is equipped with hydrophobic
and hydrophilic domains, features which provide a dual loading capacity. In this study,
G-G@HTA NPs were developed using the solvent evaporation method. This
well-defined and common procedure not only has less complexity but also is time and
cost efficient, as it involves less steps in and fewer chemicals in preparation technique as
compared to other methods124.
Additionally, tannic acid was utilized in this formulation to ensure formation of
the self-assemblies in aqueous solution, thereby adding stability and improving
biocompatibility 151 234. Accumulated evidence indicates that TA can be applied as a
reducing agent to form homogenous nanoparticles 223 234. Furthermore, we have
previously shown that TA has considerable and advantageous binding affinity with lung
fluid196, not to overlook its innate anticancer properties and intrinsic tumor targeting
hallmarks 129 76 130 230 249. Our approach was to take advantage of TA as crosslinker to
facilitate the stable formation of HTA self-assemblies by hydrophobic interaction.
Accumulated literature supports that, tannins especially TA promotes the precipitate of
macromolecules such as proteins250.
G-G@HTA nanoparticle (average size 185nm) could conveniently be utilized as a
DDS for NSCLC therapy. These results correlate with previous preclinical and clinical
trial findings, indicating that NPs in this size range not only are suitable for the
recognition of tumor tissue, but also accumulation and retention within tumor tissue as
opposed healthy tissue. For instance, Zhang et al. (2017) developed a co-assembly DDS
for gefitinib and tripeptide tyroservatide with a size of approximately 200nm, where NPs
efficiently internalize to NSCLC, and elevated antitumor efficacy in both in vitro and in
vivo studies251. Furthermore, two FDA-approved nanomedicines currently used for lung
cancer therapy, Abraxane (albumin bonded paclitaxel nanoparticle) and Genexol PM
(paclitaxel encapsulated in PEG-PLA polymeric micelles) have similar particle size
(~130 and 50nm respectively )252 253.
Successful formation of HTA NPs was confirmed with a quenching assay, FTIR
studies and TEM. Binding of the excipients and their presence in the final (G-G@HTA)
with uniform, spherical morphology was confirmed. Moreover, our HTA NPs have a zeta
potential of -22 mV. A negative charge facilitates NP internalization into cancer cells,
while also reducing the possibility of systemic toxicity.
Co-delivery of two drugs with NPs enhance the therapeutic efficacy of both
anticancer drugs as compared to systemic delivery of them as single drugs or even in
combination. For example, in a Phase II clinical trial investigation on NSCLC patients,
results indicated that the co-delivery of cisplatin-gemcitabine by a liposomal NP showed
significantly higher therapeutic efficacy with lower side effects (e.g. nephrotoxicity)
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compared to free cisplatin-gemcitabine treatment group254. In previously conducted
studies, GA has shown excellent chemo-sensitization potency in vitro and in vivo 179 191,
but it is a hydrophobic agent. Thus, incorporation of GA in a nano-carrier can conquer
this limitation, while prolonging circulation time and offering the controlled release
profile for effective and targeted delivery.
Additionally, in vitro studies exhibited enhanced antitumor efficacy of the GG@HTA NPs in comparison to the plain drugs. Moreover, the ability of cancer cells to
invade and migrate—the main cause of cancer progression—was drastically decreased
when NSCLC cell lines were treated with G-G@HTA NPs.
Further, as shown in our in vivo results (Figure 4-9), the G-G@HTA treatment
showed a superior tumor regression effect compared to free drugs with equivalent
concentrations and combination groups. As expected, the group treated with HTA alone
did not show any effect on tumor regression. Thus, the primary cause for tumor
regression in the group treated with G-G@HTA is presumably due to greater drug
accumulation in cancer cells, facilitated by the nanocarrier. As a consequence of
enhanced GA and Gem accumulation inside the cancer cells, the therapeutic effects of
these agents are increased, which should lead to a substantial reduction in
chemo-resistance, confirmed by a greater reduction in the expression level of MDR1
proteins on IHC slides from G-G@HTA NPs over plain treatments.
The elevated activation level of apoptosis at protein level was confirmed by IHC
studies, confirming the successful delivery of GA and Gem encapsulated in HTA NPs,
(by inhibition of the antiapoptotic biomarker, Bcl-2 and intracellular accumulation of
BAK in tumor cells). Furthermore, RRM2, an important prognostic marker for
NSCLC,255 256 which also correlates to Gem-resistance and survival rates in NSCLC
patients36 255 39was significantly downregulated in G-G@HTA treatment group. All
together, these results illustrate the improved apoptotic potential of G-G@HTA NPs and
also suggest that this novel formulation could ultimately lead to a reduction in
chemo-resistance.
In vivo biodistribution investigation (Figure 4-13) was done as a proof- of
concept for the tumor targeting ability of HTA NPs for clinical application and adoption.
HTA NPs in mice bearing A549 tumors demonstrated superior tumor accumulation, even
at 72h post-injection, and were able to bypass the swift elimination via the
reticuloendothelial system.
We also analyzed the fate of these nanoparticles when they are in direct contact
with blood cells. Blood chemistry panels and morphology analysis of blood cells provide
a reliable basis for general wellness in biological systems. Hematological parameters
were generally within the acceptable range of reference values, confirming a favorable
safety profile for our NPs and their cargo. Another validation for this was H&E staining
results, which did not show any obvious damage to major organs such as the heart,
spleen, lungs, kidney or liver.
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Conclusion
In summary, this study details the design of a novel nanocarrier and provides an
optimized strategy for constructing dual-loaded nanoparticles using a biodegradable, nontoxic, human serum albumin-tannic acid-based platform for GA and Gem co-delivery in
the treatment of NSCLC. The developed G-G@HTA NPs form mono-dispersed,
spherical NPs, with favorable size and surface charge, ideal for internalization into cancer
cells. These NPs show superior anticancer efficacy in in vitro and in vivo studies by
eliminating the development of chemo-resistance and by utilizing chemo-sensitization in
the setting of NSCLC.
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CHAPTER 5.

SUMMARY AND FUTURE DIRECTION
Summary

Originating from lung, bronchogenic carcinoma also known as lung cancer is the
leading causes of cancer associated death in both men and women in the United States,
with the majority of cases (85-90%) being NSCLC. Conventional chemotherapy is
currently the most effective treatment for NSCLC patients with advanced invasive
disease. The side effects of this type of therapy are often severe and intolerable,
especially for unfit patients. However, Gem a pyrimidine nucleoside antimetabolite, with
a relatively lower toxicity profile, has been used widely as an effective anticancer agent
for patients with NSCLC as well as other cancers such as pancreatic, bladder, breast, and
ovarian. But this treatment option often suffers from the rapid development of resistance,
therefore combination therapies are being investigated as the therapeutic efficacy of
combined agents together would potentially lead to an elevated level of anticancer
potency and help to overcome the Gem resistance pitfall. In this regard, there is an
emerging interest in combining chemotherapeutic agents with natural products, because
of their anticancer properties with diverse molecular mechanism and safe profile; which
leads to a robust anticancer efficacy while minimizing the undesirable side effects.
Here, we investigated the therapeutic effect of GA, a naturally occurring
xanthonoid, in combination with Gem on NSCLC. Previous studies have shown that GA
has anti-neoplastic, anticancer, and chemo-sensitization attributes75 257 258. However, to
date, there have been no documented studies on its effects in combination with Gem on
NSCLC. Our results revealed that a combined treatment of GA and Gem inhibited the
growth and proliferation of NSCLC cells, induced apoptosis and inhibit the tube
formation of HUVEC cells. Furthermore, GA sensitizes NSCLC to Gem therapy by
blocking P-gp transporter. Our results highlight potentials of this treatment option for
future NSCLC therapy.
Nevertheless, GA suffers from water solubility and its inorganic solvent may
cause systemic toxicity issues. On the other hand, the utilization of the conventional drug
delivery approach usually leads to off-target toxicity, thus, we designed the
biodegradable and biocompatible stable NPs with low immunogenicity and low toxicity.
Our in vitro and in vivo results demonstrated that our designed NDDS loaded with two
anticancer agents (GA and Gem) significantly increased their therapeutic effect while
decreased the off-target toxicity and side effects while prolongs the blood circulation as
exhibited in a xenograft mouse model.
Future Research
Taken together, the results and findings of this project, illustrate the proof of
concept that our uniquely designed dual loaded protein-based HTA NPs are capable of
increasing the therapeutic effect of GA and Gem on NSCLC, and not only lead to tumor
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regression but also have the tumor-targeting ability on a xenografic mouse model.
Furthermore, successful tumor accumulation and biodistribution of HTA NPs provides
strong supportive evidence for subsequent use in pre-clinical and clinical translation. It is
further proven that this noncarrier is capable of co-deliver hydrophobic and hydrophilic
drugs simultaneously and increase their antitumoral properties. However, this work can
be considered as a decent attempt toward the production and development of finer
nanomedicine in cancer therapy, some further research can strengthen this concept and
project are as follows. Further detailed investigation of molecular mechanism would help
to unraveling the involved signaling pathways to identifying the therapeutic target of GA
and Gem combinations on NSCLC. Also, utilization of a high-pressure homogenizer in
the process of preparation of the NPs, can assist with optimization and decreasing the
batch to batch variation and increase the loading efficacy. Inspection of the loading
efficacy and drug release profile of the G-G @HTA NPs is necessity. Moreover, to
enhance the active targeting of these NPs, they can be conjugated with different ligands
to target specific receptors abundant on cancer cells (e.g. EGFR).
Furthermore, the primary limitation of our in vivo study was utilization of
xenograft animal model, and generation of tumor by subcutaneous techniques with just
one subcategories of NSCLC, which cannot mimic the actual complex nature of NSCLC
tumors, therefore considering this preliminary in vivo study as a concept validation, a
more detailed and multidimensional model such as orthotopic mouse is required.
Additionally, as the common administration route for protein-based NPs (e.g. Abraxane)
is via intravenous injection, thus, further in vivo studies should take this in consideration
for a smoother and more predictable transition to clinical trials.
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